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Abstract 
 
Nanotechnology is the latest in a long series of technologies heralded as 
ushering in a new era and current and future applications of nanotechnology are 
expected to hold immense societal and environmental benefits. Concerns have been 
raised about the safety and regulation of nanomaterials following a number of studies 
which indicated that some nanomaterials can cause adverse effects on laboratory 
animals. Data on nanoparticles, such as increasing production volumes and 
commercialization, capabilities to cross biological barriers, and increased biological 
activities of nanoparticles when compared to bulk counterparts, have worried some 
scientists, policy-makers, members of the public and industry and investors about 
their potential impacts on the health and safety of both humans and the environment.  
The aim of this PhD Thesis is to: 1) investigate whether existing regulation is 
adequate in the short and the long term, 2) explore the feasibility of risk assessment 
for the purpose of dealing with the complex emerging risks of nanomaterials, and 
finally, 3) provide recommendations on how to govern nanotechnologies.  
The short and long term development of nanotechnologies and nanomaterials 
was investigated and an in-depth analysis was performed of key pieces of regulation 
in the EU such as REACH, pharmaceutical regulation, and the worker safety 
directives, and waste directives. The applicability of each of the four individual steps 
of risk assessment (i.e. hazard identification, dose-response assessment, exposure 
assessment, and risk characterization) was evaluated in the light of the current state of 
knowledge.  
It is found that although nanomaterials might be covered by the general scope 
of many of the existing legislative frameworks it is often unclear, if current regulation 
is actually applicable when it comes to specific nanomaterials and their diverse 
applications. The main problems seem to be: that requirements to do safety 
evaluations are triggered by production volumes by tonnage not tailored to the 
nanoscale, the profound lack of (eco)toxicological data, and that no risk thresholds 
and occupational exposure  limits cannot be established with existing methodologies.  
So far, the only amendment that has been implemented is to annul the 
exemption status of carbon and graphite under REACH, which is deemed inadequate 
to address the potential risks of nanomaterials and the current regulatory uncertainty.  
Several governments have opted to implement voluntary environmental 
programs (VEPs), arguing that this is the only viable proportional option for the time 
being. It is generally known that key elements of any successful VEP are: incentives 
to participate for various stakeholders, agency guidance and technical assistance, 
signed commitments and periodical reporting, quality of information, and 
transparency both in design, reporting and evaluation. However, many of these 
elements have not been fully addressed in the VEPs that are implemented currently on 
nanomaterials.  
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Each of the four steps, that together constitute the risk assessment framework 
hold a number of limitations as well. Toxicity has been reported on for multiple 
nanoparticles, but for most nanoparticles these need further confirmation before one 
can say that a hazard has been identified. It is currently impossible to systematically 
link reported nanoparticle properties to the observed effects for effective hazard 
identification. Although some studies have reported observing a dose-response 
relationship, it was unclear whether a no effect threshold can be established and what 
the best hazard descriptor(s) of nanoparticles is and what the most relevant endpoints 
are. The current lack of characterization of the nanoparticles tested in various studies 
makes it impossible to identify causality between observed hazards and specific 
physical and chemical properties. Several studies have tried to assess current and 
future consumer and environmental exposure for nanomaterials, but these should be 
seen as “proof of principle” rather than actual assessment of the exposure. Realistic 
exposure assessment is hampered by: paucity of knowledge, lack of access to 
information, by difficulties in monitoring nanomaterial exposure in the workplace and 
the environment, and by the fact that the biological and environmental pathways of 
nanomaterials are still largely unexplored. Risk characterization being at the end of 
the line, the sum or maybe even the power all of these limitations are conveyed to 
calculating risk quotients for nanomaterials.  
It is concluded that we do not know enough to say that nanomaterials are safe, 
but that there is evidence that some nanomaterials are hazardous depending on their 
particle characteristics, how they are applied and how humans and the environment 
are exposed to them. Although recognizing that adaptations are needed, risk 
assessment has repeatedly been proposed by expert committees, policy-makers, 
members of industry and non-governmental organizations as means to inform 
decision-makers about the risks of nanomaterials. However, in this thesis, risk 
assessment is found to be inadequate to timely inform policy-makers about the health 
and environmental risks of nanomaterials, if not in the short term, then most 
definitely, in the long term. Risk assessment is not feasible for the purpose of dealing 
with the complex emerging risks of nanomaterials and will not be adequate to ensure 
a decision-making process that enables us to make informed decisions within a 
reasonable period of time. It is furthermore concluded that the existing regulation is 
not adequate to deal with nanomaterials in the short and the long term and that too 
little is being done currently to amend existing regulation through the incremental 
approach adopted by the EU and the voluntary program implemented in the UK. It is 
recommended that current regulation is adapted immediately to reflect the challenges 
posed by current nanomaterials and their applications. Risk assessment should be 
abandoned as the primary decision making tool. Alternative tools such as 
MultiCriteria Decision Analysis, Bayesian decision making and Adaptive 
management should be pursued to ensure and support transparent and informed 
decision-making processes. 
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Dansk sammenfatning 
Nanoteknologi er den seneste i rækken af teknologier udråbt til at indvarsle en 
ny industriel æra. Nuværende og fremtidige anvendelser af nanomaterialer forventes 
at have store sociale and miljømæssige fordele, men der er blevet rejst bekymring 
omkring uønskede effekter af nanomaterialer efter et antal studier har vist, at nogle 
nanomaterialer kan forårsage skadelige effekter på laboratoriedyr. Generel viden om 
nanopartikler, så som stigende produktionsmængder, evne til at krydse biologiske 
membraner, og en øget biologisk aktivitet af nanopartikler sammenlignet med større 
partikler, har endvidere gjort videnskabsfolk, politikere, dele af befolkningen og 
industrien samt investorer bekymrede over nanopartiklers potentielle skadelige 
effekter på mennesker og miljø.   
Formålet med denne Ph.d.-afhandling er: 1) at undersøge hvorvidt den 
nuværende regulering er tilstrækkelig på kort såvel som lang sigt, 2) at belyse 
anvendeligheden af risikovurdering til at håndtere komplekse og fremspirende risici 
relateret til nanomaterialer og 3) at give anbefalinger til hvorledes nanomaterialer kan 
reguleres.  
I afhandlingen beskrives den kort- og langsigtede udvikling af nanoteknologi 
og der foretages en dybdeborende analyse af flere af de fundamentale dele af 
reguleringen i EU så som REACH, lægemiddellovgivningen og 
arbejdsmiljølovgivningen. Risikovurdering af kemikalier består af fire overordnede 
dele – farlighedsidentifikation, dosis-respons vurdering, eksponeringsvurdering samt 
risiko karakterisering. Anvendeligheden af hver af disse dele med hensyn til 
nanomaterialer bliver evalueret i lyset af den nuværende viden.  
Resultatet af undersøgelse er, at selvom nanomaterialer falder ind under det 
overordnende formål af den nuværende regulering, så er det ofte uklart hvorvidt den 
nuværende regulering er anvendelig når det kommer til specifikke nanomaterialer og 
deres vidt forskellige anvendelser. Hovedproblemerne synes at være, at krav om 
sikkerhedsevalueringen udløses på baggrund af produktionsmængde i tons, den 
fundamentale mangel på (øko)toksikologiske data og at tærskelværdier for hvornår 
der ikke er nogen risiko og grænseværdier for arbejdsmiljø ikke kan fastsættes med 
nuværende metoder. 
Det eneste tiltag, som er blevet implementeret indtil videre, er at slette karbon 
og grafit fra listen over stoffer, som er undtaget REACH. Dette vurderes at være 
utilstrækkeligt til at adressere de potentielle risici af nanomaterialer og den nuværende 
reguleringsmæssige usikkerhed.  
I Storbritannien har man valgt at indføre frivillige aftaler med virksomheder, 
der producerer nanomaterialer, med det argument, at det er det eneste proportionale 
reguleringstiltag på nuværende tidspunkt. I et af studierne i denne afhandling er det 
beskrevet, hvorledes visse elementer skal være til stede for at frivillige aftaler bliver 
en succes. Disse elementer er: incitament til at deltage for forskellige interessenter, 
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myndighedsvejledning, underskrevne forpligtigelser og periodisk afrapportering, 
kvalitetssikring af information, og gennemskuelighed i såvel design, rapportering som 
evaluering af disse frivillige aftaler. Mange af disse elementer er endnu ikke blevet 
fuldt ud implementeret i mange af de nuværende frivillige aftaler angående 
nanomaterialer.  
Hvert enkelt element af risikovurdering for kemikalier har ligeledes en række 
begrænsninger. Selvom giftighed er blevet rapporteret for flere nanopartikler, så 
mangler disse observationer at blive bekræftet for de fleste partikler, før man kan sige, 
at egentlig farlighed er blevet identificeret. På nuværende tidspunkt er det umuligt 
systematisk at forbinde de rapporterede nanopartiklers karakteristika med de 
observerede skadelige effekter, hvilket igen begrænser mulighederne for effektiv 
farlighedsidentifikation. Selvom nogle studier har observeret et dosis-respons forhold 
er det uklart hvorvidt der findes en tærskelværdi for, hvornår der ikke er nogen effekt. 
Desuden er det ikke klarlagt hvad de(n) bedste farlighedsdeskriptor(er) for 
nanopartikler er og hvad der er de mest relevante biologiske effekt parametre. Den 
nuværende mangel på karakterisering af de testede nanopartikler i de fleste studier gør 
det umuligt at identificere sammenhænge mellem farlighed og specifikke fysiske og 
kemiske egenskaber ved partiklerne. Flere studier har forsøgt at vurdere den 
nuværende og fremtidige forbruger- og miljømæssige eksponering af nanomaterialer, 
men disse studier skal anses som værende af principiel karakter og ikke faktiske 
eksponeringsvurderinger. Realistiske eksponeringsvurderinger vanskeliggøres af: 
manglende viden og adgang til viden, problemer med at måle eksponering for 
nanomaterialer i arbejdsmiljøet og miljøet, og af det faktum, at de biologiske og 
miljømæssige eksponeringsveje for en stor del er uudforsket for nanomaterialer. Som 
det sidste led i risikovurderingsprocessen bliver summen - eller måske endda potensen 
- af alle disse begrænsninger opsamlet i risikokarakteriseringen og i udregningen af 
risikokvotienter for nanomaterialer.     
Det konkluderes, at vi endnu ikke ved nok til at kunne sige om nanomaterialer 
er sikre. Desuden er der bevis for at visse nanomaterialer udgør en fare afhængig af 
deres partikelegenskaber, hvordan de anvendes, og hvorledes mennesker og miljø 
bliver eksponeret for dem. På trods af, at det generelt anerkendes, at ændringer til den 
nuværende kemikalie risikovurdering er påkrævet, så bliver risikovurdering gang på 
gang foreslået af diverse ekspertkomiteer, politiske beslutningstagere, repræsentanter 
for industrien og ikke-statslige organisationer som det primære middel til at informere 
beslutningstagere om nanomaterialers risiko. I denne afhandling findes det derimod, 
at risikovurdering er utilstrækkelig til rettidigt at informere beslutningstagere om de 
miljø- og sundhedsmæssige risici ved nanomaterialer. Det gælder dels på kort sigt og 
især på lang sigt. Risikovurdering er ikke anvendelig, når det drejer sig om at håndtere 
de komplekse risici ved nanomaterialer. Ej heller vil risikovurdering være 
tilstrækkelig til at sikre en beslutningsproces, som vil gøre det muligt at tage 
informerede beslutninger indenfor en rimelig tidsperiode. Det konkluderes endvidere, 
at den nuværende regulering er utilstrækkelig til at håndtere nanomaterialer på kort 
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såvel som på lang sigt, og at der på nuværende tidspunkt gøres for lidt for at 
modificere den nuværende regulering gennem den gradvise tilpasningspolitik, som 
man har valgt at følge i EU. Heller ikke den frivillige aftale, som man har valgt at 
indføre i Storbritannien, har vist sig at være effektiv.  
Det anbefales, at den nuværende regulering ændres med det samme, så den 
reflekterer de udfordringer som nanomaterialer og deres nuværende og fremtidige 
anvendelser giver. Der bør ses bort fra risikovurdering som det primære 
beslutningsværktøj. Alternative beslutningsværktøjer som MultiCriteria Decision 
Analysis, Bayesian decision making and Adaptive management burde efterprøves for 
at sikre og understøtte gennemskuelige og oplyste beslutningsprocesser.   
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1. Introduction 
It is hard to deny that most technologies have the potential to cause harm as well 
as do good. It is intuitive that the successful – and sustainable – use of any new 
technology will depend on discovering how to use it safely prior to its wide distribution. 
Yet history is replete with examples of technologies that were wielded without 
foresight, leaving a legacy of damage in their wake and often not achieving their full 
potential (EEA 2001).   
Nanotechnology is the latest in a long series of technologies heralded as ushering 
in a new era – the “next industrial revolution”, according to some.  Since 2000, 
nanotechnology has grown from little more than a gleam in the eyes of researchers to a 
technology projected to be worth $2.6 trillion in manufactured goods in 2014 (Lux 
Research 2006). Current and future applications of nanotechnology are expected to hold 
immense societal and environmental benefits in regard to increased economic 
development and employment, improved materials using less resources and 
environmental remediation, along with new ways of diagnostics and medical treatments 
(RS & RAE 2004, Roco and Bainbridge 2005).  
Nevertheless, as new materials based on nanoscale engineering move from the lab 
to the marketplace, have we learnt the lessons of past “wonder technologies”, or are we 
destined to repeat the mistakes of our predecessors?  
Both the potential benefits of nanotechnology and potential hazards of some 
manufactured nanomaterials have been debated in recent years, especially following a 
number of studies, which indicated that some nanomaterials can cause adverse effects 
on laboratory animals (Oberdörster 2004, Lam et al. 2004, Pollard et al. 2008). Data on 
nanoparticles, such as increasing production volumes and commercialization, 
capabilities to cross biological barriers, and increased biological activities of 
nanoparticles when compared to bulk counterparts, have worried some scientists about 
their potential impacts on the health and safety of both humans and the environment.  
Perhaps more than any preceding technology, the early development of 
nanotechnology has been characterized by discussions of potential risks.  Early on in the 
development of the United States’ National Nanotechnology Initiative, addressing risks 
was an integral part of the government-led development process. In the UK, the Royal 
Society and Royal Academy of Engineering (RS & RAE) (2004) galvanized the 
development of cross-agency groups to address uncertainties regarding the risks of 
nanomaterials. Currently, most economies investing in nanotechnology pepper 
discussions with questions concerning potential risks – and how to manage them 
(Hansen et al. 2008a).  
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The first logical questions for many politicians, regulators, academics and members of 
the public have been:  
 whether nanotechnology is safe; 
 whether existing regulation is adequate in the short and in the long term; 
 what is and should be done to learn more about protection of the public and  
workers from any potential environmental, health and safety risks related to 
nanotechnology and nanomaterials (RS & RAE 2004, Macoubrie 2005, Chaundry 
et al. 2006, Gavelin et al. 2007).  
Currently, the short answer to these questions seems to be that “we do not know”, 
“probably not” and “not enough” which leads to another underlying and more urgent 
question of whether existing decision making tools such as risk assessment are adequate 
to ensure a decision making process that enables us to make informed decisions within a 
reasonable period of time, despite large uncertainties about the risks of nanotechnology 
and nanomaterials.  
This thesis explores these and related questions.  
 
1.1 Objectives and outline 
The aim of this PhD thesis is to:  
1. investigate whether existing regulation is adequate in the short and the long 
term;  
2. explore the feasibility of risk assessment for the purpose of dealing with the 
complex emerging risks of nanomaterials, and finally;  
3. provide recommendations on how to govern nanotechnologies protecting human 
health and the environment.  
A fundamental aspect that has to be kept in mind is that nanotechnology is an 
emerging technology that it is developing with rapid speed in multiple directions and in 
many scientific fields and industrial sectors. Hence, one needs to take both current and 
reasonably foreseeable future developments and applications of nanotechnology and 
nanomaterials into consideration when discussing and trying to assess what the risks are 
and whether current regulation and decision making tools are adequate. The short and 
long term perspectives of nanotechnolgical development are introduced in section 2.  
Before one can start discussing the risks of nanotechnology and/or nanomaterials 
and the suitability of current regulation and decision making tools, it is important to 
clarify the terminology used. The “nanorisk”-terminology has not always been 
consistent. Nanotechnology and nanomaterials have often been lumped together as one 
and the same notwithstanding that the term “nanotechnology” covers many fields of 
disciplines, research, applications, etc. and not just nanomaterials. A lot of advancement 
has been made recently to address the issue of diffuse terminology, which is introduced 
in section 3.  
 3
All governments bear the direct and indirect responsibility for protecting their 
citizens against risks, but because of lack of knowledge the proper regulatory response 
is not always obvious and views on how to regulate nanomaterials vary substantially, 
ranging from a ‘‘laissez-faire’’ attitude to a total moratorium on nanotechnology 
research, development and commercialization. In section 4 the applicability and 
feasibility of the existing regulation is investigated in the short and the long term, 
focussing especially on the new chemical legislation in Europe termed REACH. 
In the past, science provided regulating authorities with essential information 
upon which they could base their regulatory decisions and justify these to the public. 
The complexity of risks in general and nanomaterials in particular makes it difficult for 
science to identify causality and provide clear answers immediately (if ever) (Weinberg 
1985, Ruckelhaus 1985, Funtowicz and Ravetz 1992, Harremoës 2003). New ways to 
inform decision makers have been sought and decision support tools such as risk 
assessment have repeatedly been proposed as means to inform decision makers about 
the risks of nanomaterials. In section 5, the feasibility of applying risk assessment to 
nanomaterials is investigated and the state of knowledge is discussed within each of  the 
four parts of chemical risk assessment i.e. hazard identification, dose-response 
assessment, exposure assessment, and risk characterization. Finally the pros and cons of 
existing regulation and risk assessment are discussed in section 6 and recommendations 
are provided.  
 4
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2. Development of nanotechnology and materials 
In order to assess the applicability of the current regulation and risk assessment 
in the short and the long term, insight is needed into current and future trends with 
regard to the development and commercialization of nanotechnology. If the current 
regulation and risk assessment is not able to deal with current nanomaterials, it is highly 
unlikely that it will be able to deal with future nanomaterials. 
The development of nanotechnology has been rapid by almost any metric one 
can think of – governmental funding, number of research publications and industrial 
patents, among others. To begin with nanotechnological development was mostly driven 
by individual scientific breakthroughs such as the discovery of fullerenes, quantum dots 
and carbon nanotubes (Iijima, 1991) along with the inventions of the scanning tunneling 
microscopy and atomic force microscopy (Kroto et al. 1986, Iijima 1991, Binning et al. 
1982, 1986).  
A turning point in science and technology policy in relation to nanotechnology 
was the increasing amount of government funding in the United States of America 
(USA) in the late 1990ties which finally lead to the launch of the National 
Nanotechnology Initiative (NNI) in 2000. Since then, almost every country on the globe 
has launched national initiatives or prioritizes research in nanotechnology, and the USA, 
Japan and the EU each spend more than a billion Euros a year on nano-related research.  
 Government funding of academic research has lead to an explosion in the 
number of scientific research publications in nanotechnology. Recently, Linkov et al. 
(2008a) performed an analysis of Science Citation Index database available through the 
Web of Science to map out nanotechnology application and data generation trends in 
regard to environment, health and safety. Using a wide range of search terms, they 
found that the total number of publications increased from just over 3,000 in 1995 to an 
estimated 52,000 in 2008. The number of papers that mention risk was less than 10 
through 2003, however, since then it has been rapidly increasing and over 100 are 
expected to be published in 2008 (see figure 1). 
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Figure 1: Number of journal articles on nanotechnology topics by year in Science Citation Index.  “All 
Nano” corresponds to all published papers resulting from a search using the string “TS=(quantum dot OR 
nanostruc* OR nanopartic* OR nanotub* OR fulleren* OR nanomaterial* OR nanofib* OR nanotech* 
OR nanocryst* OR nanocomposit* OR nanohorn* OR nanowir* OR nanobel* OR nanopor* OR 
dendrimer* OR nanolith* OR nanoimp* OR nano-imp* OR dip-pen)” with document type = article 
(search string taken from Lux Research, 2007).  “Nano Characterization” and “Nano and Risk” are a 
subset of papers that include nanomaterial characterization and risk.  The final plot represents papers co-
authored by scientists from U.S. Food and Drug Administration and U.S. Environmental Protection 
Agency. The number of articles published annually data for 2008 was estimated by multiplying the 
number of papers published in the first quarter by 4 (Linkov et al. 2008a). 
 
Scientific activities sparked by Government funding have had a crucial role in 
knowledge creation and flows in nanotechnology although there is often some time-lag 
before scientific knowledge is diffused into useful inventions and applications (Igami 
and Okazaki 2007). Patent analysis is one way to examine how knowledge flows from 
science to technological development. In an analysis of patent applications to the 
European Patent Office (EPO), Igami and Okazaki (2007) found that there have been an 
increasing number of nanotechnology patents applications in the period of 1984-2002, 
especially after 1996 (see figure 2).  
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Figure 2: Trends in nanotechnology patent applications to the EPO (Modified from Igami and Okazaki 
2007). 
 
The USA, EU and Japan each account for about a third of the nanotechnology 
patent applications each whereas Germany, France and the United Kingdom are the 
leading countries in the European Union (Igami and Okazaki 2007).  
 The substantial increase in nanotechnological patent applications filed in the 
period from 1984-2002 manifests itself in most fields of applications e.g. electronics 
and nanomaterials except for environment and energy (Igami and Okazaki 2007). It is 
interesting to note that nanomaterials were the primary field of application for which 
patent applications were filed in 2002. It should however be noted that nanomaterials 
were defined fairly broadly under EPO and include among others: chemical or physical 
processes, nano- and/or microstructures, manufacture, shaping, or supplementary 
processes, coatings and crystal growth (Igami and Okazaki 2007). 
The number of patents on nanomaterials as been increased globally as well – 
according to Royal Commission on Environmental Pollution (RCEP) (2008) the number 
of patents registered from 1990-2006 for nanoparticles, nanorod, nanowire, nanocrystal, 
nanotube or carbon nanotubes have more than doubled every 2 years. 
Governmental funding and prioritization of nanotechnology since the mid-
1990ties has lead to higher education and government sectors becoming important 
sources of knowledge in nanotechnology. This is reflected in the fact that comparatively 
larger shares of patents applications stem from government (5%) and higher education 
(8%) sectors. The business enterprise sector, however, still accounts for the majority of 
the applications (80%); it is approximately 10% lower than its share in overall EPO. 
According to the Technology Transfer Center (2007) there are more than 300 
nanotechnology companies in Europe, most of which are based in Germany and the UK. 
These companies range from multinationals to small and medium size companies and 
university spin-offs. They span over a wide range of sectors and applications (see figure 
3) including textiles, anti-microbial wound dressings, paints and coatings, fuel catalysts 
and additives, lubricants, cosmetics, and food packaging (Chaundry et al. 2006). 
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Figure 3: Market application focus of nanotechnology companies  
in Europe 2007 (Modified from Technology Transfer Center 2007) 
 
Figure 3  shows the focus of market application of nanotechnology companies in 
Europe in 2007 for which nanotechnology products or platforms are a primary area of 
business, however, it is important to realize these numbers do not include tools and 
instrumentation companies or companies that use nanotechnology without having a 
nanotechnology business unit (Technology Transfer Center 2007). 
Although much focus is and has been on research and development (R&D), 
nanotechnology is entering a new era in the sense that more and more emphasis is being 
put on commercialization of nanomaterials and products. In 2006, the Project for 
Emerging Nanotechnologies at the Woodrow Wilson International Center for Scholars 
launched an inventory of the products available online to consumers containing 
nanomaterials (the Woodrow Wilson inventory). Originally the inventory contained 212 
different products in 2006, which has increased to 580 products in 2007 and 803 in 
2008. Projections are that this number will continue to increase as the unique properties 
of nanomaterials are explored further and translated into commercial products. The 
products fall into a number of different product categories such as health and fitness, 
home and garden, electronics and computers, etc. (see figure 4). 
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Figure 4: Top chart shows the distribution of the products in the inventory according to product category. 
The 580 products fall into a number of different product categories such as health and fitness, home and 
garden, electronics and computers, etc. Bottom chart shows the materials used in the various products 
listed in inventory. The main kinds of materials used are graphite (including carbon nanotubes and 
fullerenes), silver, silica, TiO2, and ZnO. Source: http://www.nanotechproject.org/consumer/ 
analysis.html (Accessed November 6 2007). All rights reserved by Woodrow Wilson International 
Center for Scholars (Hansen et al. 2008b). 
 
From figure 4 one can see that nanomaterials are proclaimed to be used in 
products that fall mainly into the categories of health and fitness, food and beverages, 
and home and garden, whereas the silver and carbon are the nanomaterials mostly used 
(Hansen et al. 2008b). 
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The Woodrow Wilson inventory contains information such as product name, 
company, manufacturer or supplier, country of origin, and a short product description. 
However, it does not contain information about how many units are produced and sold 
of a given product or how much nanomaterial is used in each of the individual products. 
Such information is only available for a limited number of products, if producers make 
it available.  
Very little is furthermore known about the production volumes at which 
nanomaterials are currently produced, although some scattered information is available. 
In 2001, the future global annual production of carbon-based nanomaterials was 
estimated to be several hundred tons, but already in 2003, the global production of 
nanotubes alone was estimated to be around 900 tons distributed between 16 
manufacturers (Kleiner and Hogan 2003). The Japanese company, Frontier Carbon 
Corp, annually produces more than 40 tons of C60 (Fujitani et al. 2008). It is estimated 
that the global annual production of nanotubes and fiber was 65 tons equal to €144 
million worth and it is expected to surpass €3 billion by 2010 representing an annual 
growth rate of well over 60% (Cientifica 2006). Even though the information about the 
production of carbon-based nanomaterials is scarce, the annual production volumes of 
for instance quantum dots, nano-metals, and materials with nanostructured surfaces are 
completely unknown. 
The development of nanotechnology is still in its infancy. Mihail Roco of the 
U.S. National Nanotechnology Initiative has projected four generations of 
nanotechnological development. The first generation ranged up to 2000 and consisted of 
simple “passive” nanostructures. The second generation, ranging from 2000-2005 
included the development of “active (evolving function) nanostructures” such as for 
example targeted drugs and chemicals, light-driven molecular motors, nanoscale 
fluidics, laser-emitting devices, and adaptive structures.  
In the third generation we will see “systems of nanosystems”. This generation is 
projected to range from 2005 to 2010 and will include the use various syntheses and 
assembling techniques such as bio-assembling, networking at the nanoscale and 
multiscale and hierarchical architectures, robotics on surfaces, modular nanosystems, 
chemo-mechanical processing of molecular assemblies, and quantum-based nanoscale 
systems. From 2010 to 2015/2020, a fourth generation is projected to involve the 
development of heterogeneous molecular nanosystems where each molecule in the 
nanosystem has a specific structure and plays a different role (Roco and Renn 2006).  
In the light of these predictions the current production and use of nanomaterials 
is most likely not representative for the future use and production (RCEP 2008), but 
factual information is hard to obtain. The global market impact of nanotechnology is 
expected to reach 1 trillion US$ by 2015, with around 2 million workers (Roco and 
Bainbridge 2001, Chaundry et al. 2006). The overall nanofood market (including 
packaging) is one of the areas of which a substantial growth is expected.  According to 
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Helmut Kaiser Consultancy (cited in Boxall et al. 2008) it will reach US $20.4 billion 
by 2010 from estimated $7 billion in 2006. Cientifica (2006) estimate food applications 
of nanotechnologies in 2006 to be around $410 million and that these will reach $5.8 
billion in 2012.  
Besides application with regard to food packaging, processing, etc. projected 
applications include: remediation of contaminated soil and groundwater, fuel cells and 
batteries, medical applications, drinking water treatment, and weapons and explosives 
(Chaundry et al. 2006). Some estimates for the future manufacturing of nanomaterials 
have been made for instance by the Royal Society and the Royal Academy of 
Engineering.   
 
 
 
Figure 5: Global production in 2010 and 2020 estimated by RS & RAE (RS & RAE 2004) 
 
According to the RS & RAE (2004), the largest growth in estimated global 
production is expected be to structural applications such as ceramics, catalysts, coatings, 
film, etc. (see figure 5). Other areas were substantial growth is expected include single- 
and multi-walled nanotubes, TiO2, zinc, and organic light-emitting diodes for ICT-
applications, as well as nanoencapsulates, quantum dots, composites for 
nanobiotechnology. 
Especially the market of carbon nanotubes is projected to grow substantially and 
production capacities have grown enormously within recent years. It is projected that 
sales will reach $1-2 billion annually within the next four to seven years. End uses are 
primarily expected to be electronics and the automotive industry. The global enterprise 
Bayer AG have recently opened an 30 metric tons per year manufacturing plant in 
Germany bringing their total capacity up to around 60 metric tons, whereas the French 
based company Arkema are able to produce between 10 and 30 tons per year (Thayer 
2007).  
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3. Defining nanotechnology and nanomaterials 
Nanotechnology is often described as a cross disciplinary and enabling 
technology in the sense that it has roots and relevance in a wide range of scientific 
fields, including physics, chemistry, biology, material science, and electronics. This is 
reflected in the fact that the field of nanotechnology is very broad covering a wide range 
of different techniques, scientific and commercial applications and products as well as 
nanomaterials (RS & RAE 2004). A recent study of scientific publications via co-
citation analysis identified approximately 30 research areas related to nanoscience and 
materials (Igami and Saka 2007).  
A lot of effort has been put into the development of a standard terminology 
intended to support among others: patenting, commercialization, worker, public and 
environmental safety and testing, and legislation and regulation of nanotechnology (BSI 
2007a).  
The term “nanotechnology” was first used by Taniguchi in 1974 that was 
referring to the ability to engineer materials precisely at the nanometer level (RS & 
RAE 2004). However, putting forward a common “all embracing” definition of 
nanotechnology has been quite challenging.   
One of the most cited definitions is the one applied by the U.S. National 
Nanotechnology Initiative (NNI) who defines nanotechnology as follows: 
“Nanotechnology is the understanding and control of matter at 
dimensions of roughly 1 to 100 nanometers, where unique phenomena enable 
novel applications. (. . .) . At this level, the physical, chemical, and biological 
properties of materials differ in fundamental and valuable ways from the 
properties of individual atoms and molecules or bulk matter” (Nanoscale 
Science Engineering and Technology Subcommittee 2004).  
Similar, the American Society for Testing and Materials International define 
nanotechnology as: 
“A term referring to a wide range of technologies that measure, manipulate, or 
incorporate materials and/or features with at least one dimension between 
approximately 1 and 100 nanometers (nm). Such applications exploit the 
properties, distinct from bulk/macroscopic systems, of nanoscale components” 
(ASTM Int’l 2006). 
In 2004 the Royal Society and Royal Academy of Engineering found it useful to 
make a clear distinction between “nanoscience” and “nanotechnologies”. Nanoscience 
being defined as “…the study of phenomena and manipulation of materials at atomic, 
molecular and macromolecular scales, where properties differ significantly from those 
at a larger scale”. Whereas Nanotechnologies were defined as “…the design, 
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characterisation, production and application of structures, devices and systems by 
controlling shape and size at nanometer scale.” (RS & RAE 2004). 
Although the term nanotechnology is often used in singular, it should probably 
be used in plural since the term covers several technologies as indicated by a number of 
the definitions above. Some the most well-known technologies and methods include 
chemical vapor deposition, atomic force microscopy and scanning probe- and tunneling 
microscopy but according to a recent standard on the terminology for nanofabrication 
and nanomaterials from the British Standard Institute (BSI) (2007b, c) the number of 
methods, processes and techniques easily exceeds 30. The techniques can, roughly 
speaking, be divided into so-called “top down” and “bottom up” approaches. Top down 
techniques involve starting from a larger unit of material, and etching or milling it down 
to smaller units of desired shape, whereas bottom up involves progressing from smaller 
sub-units (e.g. atoms or molecules) to make larger and functionally richer structures (RS 
& RAE 2004, BSI 2007b). Top down techniques include processes such as high-energy 
ball milling, etching, sonication, and laser ablation whereas bottom up techniques 
include sol-gel, chemical vapor deposition, plasma or flame spraying, supercritical fluid, 
spinning, and self-assembly (Biswas and Wu 2005). Both approaches hold specific 
challenges. Creating smaller and smaller structures with sufficient accuracy is a main 
challenge for top-down manufacturing, whereas the challenge for bottom up techniques 
is to make structures large enough and of sufficient quality (RS & RAE 2004). 
Although the wording differs, most definitions of nanomaterials require that two 
criteria must be fulfilled in order to define a system or material as being related to 
nanotechnology: 1) It must have some structure in at least one dimension in the 
approximate range of 1-100 nm, and 2) this nanostructure must give the system 
properties differing from the bulk properties. Although this definition is broad, this does 
not make it diffuse, and for a given material or system it can be uniquely determined 
whether it involves nanotechnology or not (Hansen et al. 2007). 
The number of nanomaterials that can be manufactured using top down and 
bottom up techniques is immense including, for instance, C60, carbon nanotubes, 
micelles, self assemble monolayers, dendrimers, and aerogels in all kinds of size and 
shapes. Hence the nature of nanomaterials differs even more than the techniques.   
A procedure for dividing nanomaterials into relevant subcategories has been 
developed by Hansen et al. (2007) in order to facilitate hazard identification and to 
focus the risk assessment procedures (see figure 6).  
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Figure 6. The categorization framework for nanomaterials. The nanomaterials are categorized 
according to the location of the nanostructure in the material (Hansen et al. 2007). 
 
Hansen et al. (2007) suggest categorizing nanomaterials depending on the 
location of the nanoscale structure in the system. This leads to a division of 
nanomaterials into three main categories: 
1. materials that are nanostructured in the bulk; 
2. materials that have nanostructure on the surface and;  
3. materials that contain nanostructured particles. 
The main categories can be further divided into subcategories. The main category I 
contains materials that are nanostructured in three dimensions, i.e. in the bulk of the 
material. It is divided into two subcategories: Ia and Ib. The systems in Ia consist only 
of one type of material whereas systems in Ib are nanostructured throughout the bulk as 
well, but consist of two or more different constituents/materials. In category II the 
nanostructure is on the surface. The first subcategory, IIa, consists of materials where 
the surface is structured on the nanoscale, but the surface and bulk consist of the same 
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material. The second subcategory, IIb, covers un-patterned film of nanoscale thickness 
on a substrate of a different material. The third category, IIc, consists of patterned film 
on a substrate, where the film is either nanoscale in thickness, or the pattern has 
nanoscale dimensions along the surface. Category III contains nanoparticles, which 
Hansen et al. (2007) define as free structures that are nanosized in at least two 
dimensions much like the ASTM definition of nanoparticles (ASTM Int’l 2006). 
Nanostructured particles can have various forms and shapes and this category includes 
for example quantum dots, fullerenes, nanotubes and nanowires (Maynard and Aitken 
2007). There are four subcategories of systems with nanoparticles, depending on the 
environment around the nanoparticles:  
1. subcategory IIIa have nanoparticles bound to the surface of another solid 
structure;  
2. subcategory IIIb consists of systems where nanoparticles are suspended in a 
liquid; 
3. subcategory  IIIc is nanoparticles suspended in solids 
4. subcategory IIId, consists of airborne nanoparticles. 
Using the framework for categorizing nanotechnology-based systems, it should 
be recognized that it is possible for a system to consist of nanostructured elements 
belonging to different categories. An example of this is car catalysts used to remove 
NOx from car exhaust (Chorkendorff & Niemantsverdriet 2003). The chemical reaction 
that removes NOx is catalyzed by Platinum and Ruthenium nanoparticles of 2-3 nm 
size. These nanoparticles are bound to the surface of a support material. This 
corresponds to a category IIIa system according to figure 6. At the same time, the 
support material is a nanoporous material consisting mostly of g-Al2O3 (70-85%) and 
other oxides such as cerium oxide or lanthanum oxide. Thus, the support structure is a 
category Ib system.  
A major benefit of the proposed categorization framework is that it provides a 
tool for dividing nanosystems into identifiable parts and thereby facilitating evaluations 
of, for instance, relevant exposure routes or analysis of effect studies according to 
relevance of the material tested.  
Using the framework, Hansen et al. (2008b) were able to categorize about 75% 
of the (at the time) 580 products in the consumer product inventory maintained by the 
Project for Emerging Nanotechnologies at the Woodrow Wilson International Center for 
Scholars. Figure 7 shows the distribution of all the products categorized according to the 
location of the nanostructure in the products. It was found that in 19% of the products 
the nanomaterial were nanoparticles bound to the surfaces. Nanoparticles suspended in 
liquids were used in 37% of the products, whereas 13% used nanoparticles suspended in 
solids. 1% were powders containing free potentially airborne nanoparticles, whereas we 
were not able to determine the location of the nanomaterial for 140 products given the 
available information from producers or through the data in the inventory.  
 17
 
Figure 7: Products in the Woodrow Wilson inventory categorized depending on the location 
of the nanostructure. 13, 19, 37 and 1% of the products used nanoparticles suspended in 
solids, bound to the surfaces, suspended in liquids, and free potentially airborne nanoparticles, 
respectively (Hansen et al. 2008b). 
 
Although they have the same size range and may have several physical 
characteristics in common, Oberdörster et al. (2007) proposed making a distinction 
between ultrafine particles that are generated as heterogeneous aggregates of primary 
particles and engineered nanoparticles that are generated as more monodispersed 
individual particles. This would divide ultrafine nanoparticles into two overall 
categories: natural and anthropogenically generated particles for which the later again 
can be divided into unintentionally and intentionally generated particles.  
The framework proposed by Hansen et al. (2007) is limited to nanoparticles that 
have been humanly engineered intentionally - henceforth referred to as engineered 
nanoparticles - and does not include nanoparticles that are naturally occurring (e.g. 
forest fires and volcanoes) and unintentional human generated nanoparticles stemming 
from for instance internal combustion engines, power plans and incinerators 
(Oberdörster et al. 2007). 
Nowack and Bucheli (2007) also propose dividing nanoparticles into “natural” 
and “anthropogenic” particles depending on their source of origin. Both of these 
categories can be separated into carbon-containing and inorganic nanoparticles. The 
first category includes “biogenic, geogenic, atmospheric and pyrogenic particles such 
as fullerenes and carbon nanotubes of geogenic or pyrogenic origin, biogenic magnetite 
or atmospheric aerosols (both organic, such as organic acids, and inorganic, such as 
sea salt).” The second category of anthropogenic nanoparticles include particles 
inadvertently formed as a by-product, or produced intentionally, i.e. engineered or 
manufactured nanoparticles. 
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Various international standardization institutes have shifted attention from trying 
to define nanotechnology to defining the nature of the many different kinds of 
nanoparticles. Recently the BSI (2007d) published a standard on the terminology on 
“carbon nanostructures” defining, for instance, carbon nanotubes as hollow nanorods of 
carbon with nanorods being defined as nano-object with two similar external 
dimensions in the nanoscale and the third dimension significantly larger. The 
International Organization for Standardization (ISO) 2008) has also published 
definitions on nanotubes, nanorods, and quantum dots, for instance defining the later as 
crystalline nanoparticles that exhibits size-dependent properties due to quantum 
confinement effects on the electronic states. 
The many and sometimes conflicting definitions raise the question/problem of 
how to resolve the fact that we now have many potential competing standards in an area 
that needs greater certainty and not additional confusion (Monica 2008). Recently, 
concerns have been raised that this could have further complicated the efforts to develop 
sensible, effective policy (Center for Responsible Nanotechnologies 2008).  
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4. Regulation of nanomaterials 
The first logical questions for many politicians, regulators, academics and 
members of the public, have been whether existing regulation is adequate in the short 
and the long term and what should be and is being done to address any potential 
regulatory gaps related to nanotechnology and nanomaterials (RS & RAE 2004, 
Macoubrie 2005, Chaundry et al. 2006, Gavelin et al. 2007).  
Opinions on the applicability of the existing regulation differ substantially and 
so does views on which regulatory options best address the current lack of information 
about environment, health and safety risks of nanomaterials, as well as the regulatory 
uncertainty and concerns expressed by the politicians, members of the public and 
industry, and investors. Some argue that a complete new regulatory framework is 
needed, whereas others argue in favor of implementing a total moratorium on 
nanotechnology research, development and commercialization. Again others adopt a 
‘‘laissez-faire’’ attitude.  
Understanding the limitations of the current regulation in regard to 
nanomaterials is a starting point in the process towards adapting existing laws and 
facilitating discussion about which kind of regulatory options is best to address these.  
The identification of gaps or limitations of the current regulation of 
nanomaterials has been subject to intense international scrutiny. Some have used a very 
horizontal approach to evaluate the applicability of the current regulation to 
nanomaterials as a whole without any specific technology, nanomaterials, application, 
product or sector in mind (CEC 2008a). Others have analyzed the current regulation 
using a sector-by-sector approach in regard to current and future applications of 
nanomaterials (Chaundry et al. 2006), whereas others have looked at the regulation of 
specific commercialized products along their life-cycle (Franco et al. 2007). In the 
following, the results of these will be presented with regard to some of the major 
regulatory frameworks relevant to nanomaterials. These include REACH, 
pharmaceutical regulation, food laws, worker safety directives, and environmental 
legislation i.e. waste directives.    
 
4.1 Registration, Evaluation and Authorization of Chemicals (REACH)  
June 1, 2007, a new chemical legislation on the manufacturing and 
commercialization of chemical substances in the European market went into force. The 
new regulation, termed Registration, Evaluation and Authorization of CHemicals 
(REACH), establishes an authorizing system that requires the registration and 
evaluation of existing and new chemical substances (EP & CEU 2006). 
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In a horizontal scoping study, Chaundry et al. (2005) assessed the gaps in 
environmental regulation in the UK and the EU, media by media and sector by sector 
focusing on current and future products and applications of nanomaterials. In total 16 
different sectors were included among others coatings, construction, and cosmetics.  
One of the limitations identified by Chaundry et al. (2005) was related to 
whether a nano-equivalent of a substance with different physicochemical and (eco) 
toxicological properties from the bulk substance would be considered as the same or as  
new substances under REACH. REACH defines a substance as “a chemical element 
and its compounds in the natural state or obtained by any manufacturing process, 
including any additive necessary to preserve its stability and any impurity deriving from 
the process used, but excluding any solvent which may be separated without affecting 
the stability of the substance or changing its composition.” (EP & CEU 2006).   
Whether nanomaterials is considered to be a equivalent or different to the bulk 
material will have a major impact on the requirements put on manufacturers prior to 
placing nanomaterials on the market. If a nanomaterials is considered to be a different 
substance, hazard information would have to be generated for the registration dossier if 
produced in more than 1 tons/year. On the other hand, if the nanomaterial are 
considered to be the same as a registered bulk material, the appropriateness of the 
hazard information data would be open to discussion (Chaundry et al. 2006). Recently 
the European Commission published a review of the applicability of REACH arguing 
that although there is no specific provisions in REACH referring to nanomaterials the 
definition of “a chemical substance” covers nanomaterials (CEC 2008a). The 
Commission further states that: ”When an existing chemical substance, already placed 
on the market as bulk substance, is introduced on the market in a nanomaterial form 
(nanoform), the registration dossier will have to be updated to include specific 
properties of the nanoform of that substance. The additional information, including 
different classification and labelling of the nanoform and additional risk management 
measures, will need to be included in the registration dossier. The risk management 
measures and operational conditions will have to be communicated to the supply 
chain”. It is, however, highly unclear how companies should do this. Companies are 
urged to use already existing guidelines, however, both the Commission of the 
European Communities (CEC 2008a) as well as the its Scientific Committee on 
Emerging and Newly-Identified Health Risks (SCENIHR 2007) and others have pointed 
out that current test guidelines that support REACH are based on conventional 
methodologies for assessing chemical risks and may not be appropriate for assessing 
risks associated with nanomaterials. This means that although manufacturers and 
importers might be required to provide a Chemical Safety Assessment (if they produce 
or import nanomaterials in volumes more than 10 tons) they cannot rely on the 
toxicological profile of the equivalent bulk material and they cannot use existing test 
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and risk assessment guidelines since these might not provide any meaningful results or 
be practically applicable due to the limitations of conventional methods.  
Until recently carbon and graphite were exempted from registration under 
REACH, however this exemption was redrawn to address concern raised about carbon 
based nanomaterials (C & EN 2008). Companies will now have to register these 
materials if produced in quantities above one ton per producer or manufacturer per year. 
If it is produced in quantities greater than 10 tons per year a Chemical Safety 
Assessment has to be undertaken and if it meets the criteria for classification as 
dangerous or a PBT (Persistent, Bioaccumulable and Toxic) or vPvB (very Persistent 
and very Bioaccumulable), the manufacturer is required to develop exposure scenarios 
and undertake risk characterisation(s). So far no nanomaterial has been classified as 
such. It should be noted that a Chemical Safety Assessment can also be required if a 
nanomaterial is selected for further evaluation by a Member State or by the European 
Chemicals Agency due to specific concerns; or if a substance is a CMR (Carcinogenic, 
Mutagenic, or toxic for Reproduction), PBT, vPvB, ED (Endocrine Disrupting), or 
substance of equivalent concern. 
Even despite the recent amendments to REACH withdrawing carbon and 
graphite from the list of exemptions, it is highly unclear whether this would involve any 
additional obligations from producers of C60 and carbon nanotubes as well as from 
producers or importers of the final products containing C60 and carbon nanotubes, given 
what is known and accessible information about production, product contents, and 
expected consumer exposure (Franco et al. 2007). Another issue raised by Franco et al. 
(2007) is whether the annual production should be measured including impurities. All 
carbon based nanomaterials contain some degree of impurities due to the manufacturing 
process, however, a substance with a different degree of purity and composition can be 
classified as the same substance, provided hazardous properties do not differ 
significantly. This means that for instance, raw soot, NanomBlack® and purified 
fullerenes from the production of C60 could all be classified as the same, provided that 
the hazardous properties do not differ significantly.  
Although there is no tonnage related exemption under REACH for authorization, 
restriction or classification and labeling requirements, a second limitation of REACH is 
that “Substances manufactured or imported in volumes of less than 1 tons/year do not 
need to be registered” and hence producers or importers are not required to provide 
toxicological data and assess environmental exposure. As noted by Chaundry et al. 
(2006) and Franco et al. (2007) this threshold would hardly be reached for many 
nanoparticles. Chaundry et al. (2006) estimates that the majority of applications is likely 
to fall outside the scope of REACH on the basis of the low tonnage currently used in 
gram to kilogram quantities. Furthermore, the usually low concentration of 
nanoparticles in the final article is likely to exclude many nanoengineered articles from 
the REACH legislation, since no registration is required when the concentrations of a 
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substance is lower than 0.1% w/w. However, a general lack of access to information 
about product formulations and nanoparticles concentration hampers determination of 
concentrations of substances by weight (Franco et al. 2007). 
 
4.2 Pharmaceutical regulation 
The application of engineered nanoparticles for medical use offers immense benefits 
within areas like diagnosis, targeted drug delivery, and drug development and have been 
marketed for more than 17 years (NanoRoad SME 2006, EGE 2007, Gaspar 2007). 
Well-described and understood medicinal products containing nanoparticles in the form 
of liposomes, polymer protein conjugates, polymeric substances or suspensions have 
been given Marketing Authorizations within the EU under the existing regulatory 
framework e.g. Regulation 726/2004 on authorization and supervision of medicinal 
products for human and veterinary use, Directive 2001/83/EC on medicinal products for 
human use, Directive 93/42/EEC concerning medical devices, Directive 90/385/EEC 
relating to active implantable medical devices, and Directive 98/79/EC on in vitro 
diagnostic medical devices (EP & CEU 2004, Council of the European Communities 
1990, 1993, 1998, 2001).  
There is no specific mentioning of nanomedicine in the EU legislation on medicinal 
products and devices, tissue engineering and other advanced therapies. None of these 
regulations or directives was written with nanomedicinal applications in mind and 
although their scope covers nanomedicine they have been accused for being general and 
non-specific and fraught with concerns and difficulties when it comes to dealing with 
drugs more complex than traditional ones (Editorial 2007, D'Silva and Van Calster 
2008).  
The use of nanoparticles in nanomedicine has not been subject to much regulatory 
scrutiny since existing laws and regulatory instruments are believed also to cover 
medical products based on nanotechnology. The extensive testing requirements prior to 
marketing of medicine may also contribute to the notion that the potentially negative 
effects will be discovered prior to marketing, that patients are adequately informed 
about negative side-effects, and that benefits outweigh the risks or the adverse effects, 
should such be found to occur (EGE 2007, N&ET Working Group 2007) .  
However, concerns have been raised that risk assessment, safety and quality 
requirements for medicine have to be fulfilled by conformity to established quality 
systems and published product standards that may not be suitable designed to address 
various aspects relating to nanomedicine. According to the European Medicines Agency 
(EMEA) (2006), this might be especially relevant when it comes to novel applications 
of nanotechnology such as nanostructure scaffolds for tissue replacement, 
nanostructures that allow transport across biological barriers, remote control of 
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nanoprobes, integrated implantable sensory nanoelectronic systems and multifunctional 
chemical structures for drug delivery and targeting of disease.  
It is furthermore unclear whether novel nanomedicine is to be regulated as a 
medicinal product or as a medical device (EGE 2007). Currently the mechanism of 
action is key to decide whether a product should be regulated as one or the other, 
however, nanomedicinal products may exhibit a complex mechanism of action 
combining mechanical, chemical, pharmacological and immunological properties, and 
combining diagnostic and therapeutic functions. Hence many of these novel 
applications are likely to span regulatory boundaries between medicinal products and 
medical devices (EGE 2007, EMEA 2006).   
Another aspect of nanomedicine is, however, often neglected (Linkov et al. 2008b). 
It is the question what happens after the prescribed use when residues of nanomedicine 
enter the environment? It is not difficult to imagine that residues of nanomedicine or 
nano-sized drug carriers could have unexpected effects on the environment, just as it has 
been the case for conventional medicine for which a rapidly increasing number of 
laboratory studies show ecotoxicological effects (Fent et al. 2006). However, to the best 
of our knowledge no study exploring the environmental effects of nanomedical products 
has been published to date (Hansen et al. 2007). In the EU, all new marketing 
authorization applications are required to undergo an environmental risk assessment 
following a tiered assessment procedure. One significant difference in the EU risk 
assessment approach for medical products compared to that of industrial chemicals is 
the inclusion of a pre-screening stage involving a rough calculation of the predicted 
environmental concentration for surface water with an action limit of 0.01 ppb (EMEA 
2006). Thus, if the estimated environmental concentration is below this value and “no 
other environmental concerns are apparent” (European Medicines Agency 2006), no 
further actions are to be taken for the medical product in terms of environmental risk 
assessment.  
These approaches, in which the estimated environmental concentrations are used 
as trigger values for further action, are problematic if the current regulation of medical 
products is transferred directly to regulation of nanomedical products. The 
concentration limits are not set science-based and can by no means be interpreted as 
“environmentally safe concentrations” for medical products in general (also mentioned 
in the European guidelines (European Medicines Agency 2006) nor for nanomedical 
products in specific. Here a pre-defined action limit will be especially problematic since 
the new properties of nano-based products are expected to also affect their 
environmental profiles, as argued by several authors, e.g. Zhang et al. (2007) and Baun 
et al. (2008).  
Although an initial weighing of benefits versus harm may be needed to avoid 
over-regulation, it should be stressed that the evaluation of environmental fate and 
effects of engineered nanoparticles used in medical products is significantly different 
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from that of conventional pharmaceuticals. The establishment of a fixed value for a 
level-of-no-concern, where the benefits outweigh the risks, is not scientifically 
justifiable given the present level of knowledge. Not only is the amount of laboratory 
data limited and field studies and exposure models nearly non-existing – we may not 
even know the ecotoxicological endpoints to investigate and how to measure exposure 
to engineered nanoparticles in the environment.  
Many of the shortcomings to existing approaches for determining the ecotoxicity 
apply for nanomedical products as well as for nanoparticles. For two parameters used 
today to identify environmentally hazardous compounds, i.e. persistence and 
bioaccumulation, the SCENIHR concluded that: “The criteria used for persistence, 
bioaccumulation and toxicity (PBT) assessment applied for substances in soluble form 
should be assessed for applicability to nanoparticles” (SCENIHR 2007). Thus, the 
present use of the octanol-water coefficient (as a surrogate value for bioaccumulation 
data to signify environmental concern) in the EU guidelines for risk assessment of 
medical products should not be transferred to a regulation of nanomedicine unless 
strong scientific evidence supports this (Handy et al. 2008, Baun et al. 2008). 
 
4.3 Nanofood laws 
In the EU, food and food packaging are regulated by a number of laws, 
directives and regulations such as EU Food Law Regulation and the EU Novel Foods 
Regulation (EP & CEU 2002). The EU Food Law Regulation requires all food to be 
safe, something which – as an overarching principle – applies to all foods and food 
packaging containing nanomaterials as well, but has been criticized for being too loose 
(FOE 2008). None of the existing EU regulations applicable to agriculture, food or food 
packaging currently consider or mention nanoscale products or materials. If a substance 
has already been approved for use as food ingredients, additives or packaging in its bulk 
form, it can also be used in this nano form since there is no regulatory trigger to require 
new safety assessment or labeling due to particle size (FOE 2008).  
The existing regulation regarding food additives is in the process of being up-
dated in the EU. During this process the European Parliament’s Committee on 
Environment, Public Health and Food Safety last year stated that it wanted separate 
limit values for nanotechnologies and that the permitted limits for an additive in 
nanoparticle form should not be the same as when it is in traditional form (Halliday 
2007).  
The EU Novel Foods Regulation requires mandatory pre-market approval of all 
new ingredients and products. Recently, the European Commission adopted a proposal 
to revise the Novel Foods Regulation with a view to improving the access of new and 
innovative foods to the EU market (CEC 2008b). In the revised regulation the definition 
of novel food includes foods modified by new production processes, such as 
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nanotechnology and nanoscience, which might have an impact on the food itself. Once 
the European Commission receives an application for authorization of a novel food and 
its use as an ingredient, the European Food Safety Authority (EFSA) evaluates whether 
or not it presents a danger to consumers or misleads them. The regulation requires 
assessments by EFSA on the composition, nutritional value, metabolism, intended use 
and the level of microbiological and chemical contaminants. Studies on the toxicology, 
allergenicity and details of the manufacturing process may also be considered. 
However, the regulation makes no distinction in relation to particle size, and hence 
nanoparticles will not require new safety assessments if the substance has already been 
approved in bulk form. EFSA is currently preparing a scientific opinion on the potential 
risks arising from the use of nanotechnology in food. A Draft Opinion was published for 
public consultation in which EFSA concludes that that nanotechnology aspects shall be 
considered when risk assessment guidance documents in the food and feed area are 
reviewed, and among others recommend that risk assessment of nanomaterials in the 
food and feed area should consider the specific properties of nanomaterials in addition 
to those common to the equivalent non-nanoforms (EFSA 2008).  
 
4.4 Safety at Workplace Directives 
There is no direct reference to the potential exposure of engineered nanoparticles 
in the Safety at Workplace Directives or in the communitarian and national legislation 
on the protection of workers’ health at workplaces (Franco et al. 2007). However, 
according to the Commission of the European Communities (2008) they fully apply to 
nanomaterials and “…employers, therefore, must carry out a risk assessment and, where 
a risk is identified, take measures to eliminate this risk.” 
The Framework Directive 89/391 as well as Directive 98/24 on the risks associated 
with chemical substances set guidelines to establish Occupational Exposure Limits 
(OELs) for workers (Council of the European Communities 1989, 1998). However, 
there are three main problems associated with the establishment of OELs for workers at 
this point:   
1) The establishment of OELs is typically based on a complete risk assessment 
procedure which is presently not possible for engineered nanoparticles;  
2) OELs are based on mass concentration being a proper metric for toxicity, but the 
most optimal parameter(s) to determine nanoparticle toxicity is still undefined; 
3) Nanoparticles are not easily detected and monitored in the workplace and it is 
unclear whether existing personal protective equipment is adequate (Franco et 
al. 2007). 
At the moment, manufactures refer to OELs set for metal dusts or dusts of other 
compounds (e.g. graphite or carbon black instead of C60 and carbon nanotubes). 
However, given the recent concern about the toxicity of airborne carbon nanotubes, 
 26
OELs defined for related bulk substances (e.g. graphite), are not representative and 
should not be used since properties displayed by nanoparticles differ substantially from 
those of their bulk material (Lam et al. 2004).  
Problems associated with establishing OELs are reflected in many of the Material 
Safety Data Sheets (MSDSs) made available by the producers, many of which classify 
carbon nanotubes as graphite. In addition, a list of exposure control measures are 
recommended in the MSDS if ‘‘engineering controls do not ensure that the OEL is not 
exceeded’’, while the absence of any OEL is mentioned a few lines below. These 
problems and inconsistencies reveal serious gaps in the Safety at Workplace regulation, 
considering that the MSDSs are essential in passing information about risk and safety 
down the supply chain and that they also provide workers and emergency personal with 
information about the risks, protective equipment and proper handling of a substance 
(Franco et al. 2007).  
 
4.5 Waste management of products containing nanoparticles 
Waste containing nanoparticles are produced at different phases of the life cycle, 
from by-products generated during manufacturing and purification processes to 
nanoengineered goods, becoming waste at the end of their lifetime. There are no 
specific references to engineered nanoparticles in existing laws and hence nano-waste 
are tackled by waste management regulations in a non-specific way (Franco et al. 
2007). In general, nanoparticles will follow the material or the substance in which they 
are contained and their fate depends on the way this waste is treated. In some cases the 
nano-waste can fall within a particular waste category, such as if C60 is used in oil 
lubricants and the exhausted oil lubricant is specifically regulated (Franco et al. 2007). 
In other cases nanoparticles which are contained in products are typically disposed of in 
landfills or incinerated. Very little is known about the long-term behavior of 
nanoparticles in a landfill. Release depends on the nanoparticles’ mobility as well as on 
the degradability of the host material for fixed particles. When products are incinerated, 
the thermal properties of nanoparticles determine their fate. For example, a study by 
Cataldo (2002) demonstrated that C60 molecules are much easier to degrade than carbon 
nanotubes. Further, in a combustion chamber C60 behaves like graphite, while carbon 
nanotubes, similar to diamonds, are stable until very high temperatures.  
If a certain nano-waste falls within the scope of Council Directive 1991/689 on 
the management of hazardous waste (Council of the European Communities 1991), 
more severe obligations would apply. Again, the lack of (eco)toxicological data makes 
it difficult to state if nanoparticles meet the criteria of hazardousness (Franco et al. 
2007). 
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4.6 New nanospecific legislation vs. the “Incremental” approach and/or Voluntary 
Environmental Programs 
A number of limitations were identified in section 4.1-4.5 above. First of all, 
although nanomaterials might be covered by the general scope of many of the existing 
legislative frameworks, it is often unclear if nanoparticles actually are covered 
specifically by current legislation when it comes to specific nanomaterials and 
applications. The main problems seem to be that metrology tools are unavailable, that 
thresholds are not tailored to the nanoscale, but based on bulk material, profound lack of 
(eco)toxicological data, and that no risk thresholds and occupational exposure limits 
cannot be established with existing methodologies.  
Given the gaps and limitations of the current regulation, the questions on 
whether or not and how to regulate the manufacture and commercialization of 
nanomaterials have become subject to heated debate internationally, and the answer has 
been hard to come by, due to the pervasive uncertainty about the environmental and 
health risks of nanomaterials.  
During the last few years, several legislative policies have been proposed and 
discussed by public institutions like, i.e. the European Commission, Health and 
Consumer Protection Directorate General (2004), RS & RAE (2004), U.S. 
Environmental Protection Agency (U.S. EPA) (2007) and non-governmental 
organizations like i.e. ETC Group (2003) and Environmental Defense (Balbus et al. 
2007). The different views on how to regulate nanomaterials vary substantially, ranging 
from a ‘‘laissez-faire’’ attitude to a total moratorium on nanotechnology research, 
development and commercialization. A number of different kinds of regulatory options 
are available for decision makers with regard to nanomaterials. These include 
implementing a new regulatory framework, various command-and-control measures, 
voluntary environmental programs, etc.  
Currently, the possibility of a specific regulation on nanomaterials is considered 
unfeasible in the European context, due to the difficulty of establishing links between 
strikingly different pieces of legislation and the need to negotiate internationally in 
order to establish a sensible specific, in-depth regulatory process (European 
Commission, Health and Consumer Protection Directorate General 2004). Instead, the 
European Commission has adopted a so-called “incremental approach”, which focuses 
on adapting existing laws to regulate nanotechnologies. This approach is defined as the 
launch of a process which uses existing legislative structures to the maximum, revisits 
them, and, when appropriate only, amends them in order to deal with nanomaterials.  
However, so far, the only amendments that have been implemented in the EU 
are to cut carbon and graphite from the list of substances exempted from registration 
under REACH – arguably dissatisfactory to address the current regulatory uncertainty 
and the concerns expressed by the politicians, members of the public, industry and 
investors and insurers.   
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Several governments have opted to implement voluntary environmental 
programs (VEPs), arguing that this is the only viable proportional option for the time 
being (Hansen and Tickner 2007, DEFRA 2006a, 2006b, US EPA 2007, Weiss 2005). 
One such VEPs is the Voluntary Reporting Scheme for Nanomaterials established by 
the Department for Environment Food and Rural Affairs (DEFRA) in the UK. The 
reporting scheme for engineered nanoscale materials was established in 2006 in 
response to a highly cited Royal Society and Royal Academy of Engineering report (RS 
& RAE 2004) and the UK Government response to that report (HM Government 2005). 
Both of these reports identified large areas of uncertainty about: 1) the risks posed by 
engineered nanomaterials, and 2) the types of nanomaterials that will become most 
widespread within industry in the UK. The purpose of the DEFRA scheme is to, 
“develop a better understanding of what types of engineered nanoscale materials are 
likely to be produced in the UK, and to build up an understanding of their properties 
and characteristics so that the potential hazard, exposure and risk associated with these 
materials may be determined.” (DEFRA 2006) The program is intended to run for two 
years. It begins by engaging industry to submit existing data on the characteristics of 
engineered nanoscale free materials, including information on material characterization, 
hazard, use and exposure potential, and risk management practices. Submission of all 
available information is encouraged and lack of a complete package of data should not 
keep companies from reporting under the scheme (DEFRA 2007). However, DEFRA 
does not request that industry develop new data and even discourages industry from 
generating any additional data that would require animal testing (DEFRA 2006). After 
more than 2 years of implementation only eleven submissions have been received by 
DEFRA, two from academia and nine from industry (DEFRA 2008). The results to date 
have been disappointing given that a recent report have identified more than 60 
companies in the UK for which nanotechnology is the primary area of business whereas 
another report found that 372 companies there involved in micro- and 
nanomanufacturing in the UK (NMT Network 2005, Technology Transfer Center 2007).  
It remains to be seen whether and to what extend voluntary measures will be 
enough to generate the up-to-date and relevant health and safety information needed to 
perform risk assessments to support and implement regulations. It is generally known 
that key elements of any successful VEP are: incentives to participate for various 
stakeholders, agency guidance and technical assistance, signed commitments and 
periodical reporting, quality of information, and transparency both in design, reporting 
and evaluation. However, Hansen and Tickner (2007) recently found that many of these 
elements have not been fully addressed in the VEPs that are  implemented currently on 
nanomaterials – neither in the UK or anywhere else.  
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5. Risk assessment of nanomaterials 
The analysis of the applicability of the current regulation on nanomaterials 
showed that among other (eco)toxicological data and risk assessments are often 
necessary to support and implement regulations.  
At the moment, risk assessment methodologies are being discussed, evaluated 
and refined with great vengeance internationally with the hope that in the future, we will 
be able to perform complete scientifically valid quantitative risk assessments of 
nanomaterials. It is generally assumed that once such risk assessments have been 
completed, this will lead to informed risk management decisions protecting human 
health and the environment while reaping the benefits of nanotechnology for society. 
When risk assessment of nanomaterials is discussed, it is often in the context of 
previous experience with chemical risk assessment, consisting of four parts – hazard 
identification, dose-response assessment, exposure assessment, and risk 
characterization. In Europe, legislation for controlling the production, use and release of 
chemical substances is based on risk assessment, as described in detail in the “Technical 
Guidance Document” (TGD) (European Commission JRC 2003a). The TGD totals a 
staggering 1000 pages and is issued by the European Commission to help competent 
authorities to carry out risk assessments. It includes extensive technical details for 
conducting hazard identification, dose (concentration) – response (effect) assessment, 
exposure assessment and risk characterization in relation to human health and the 
environment (European Commission JRC 2003a, 2003b, 2003c, 2003d). 
The purpose of this chapter is not to do a complete risk assessment in 
accordance to the TGD, but to assess the applicability of each of the four elements of 
risk assessment with regard to nanomaterials. In this process, the current state of 
knowledge will be addressed and the most significant findings will be highlighted in 
relation to each of the four parts of risk assessment.  
 
5.1 Hazard identification  
Hazard identification is defined as the “identification of the adverse effects 
which a substance has an inherent capacity to cause” (European Commission JRC 
2003a). However, until recently the potential negative effects of nanomaterials on 
human health and the environment were rather speculative and unsubstantiated. This has 
changed within the past few years and a number of laboratory studies have indicated 
that exposure to some nanoparticles can lead to adverse effects in the lungs and the 
brain of test animals (Lam et al. 2004, Oberdörster 2004, Pollard et al. 2008).  
In a recent review, Hansen et al. (2007) identified 428 studies reporting on the 
toxicity and ecotoxicity of nanoparticles. The studied materials have mainly been 
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nanoparticles suspended in water belonging to category IIIb in figure 6 (Oberdörster 
2004, Sayes et al. 2005), but also some studies with airborne nanoparticles (category 
IIIc in figure 6) have been carried out (Baggs et al. 1997, Cheng 2004, Baker et al. 
2005).  
Figure 8 shows the distribution of these studies divided into cytotoxicity, 
mammalian toxicity, DNA damage, microbial test and ecotoxicity. In total, the studies 
reported the observed adverse effects of 965 tested nanoparticles of various chemical 
compositions.  
  
 
 
Figure 8: Distribution of studies on nanoparticles describing cytotoxicity, mammalian toxicity, microbial 
tests, DNA damage, and ecotoxicity of engineered nanoparticles. Total number of studies: 472 (Hansen et 
al. 2007a) 
 
The scientific literature on the environmental, health and safety of nanomaterials 
has been reviewed multiple times by both national and international scientists, agencies, 
and governments. In the following, a number of significant scientific studies and 
findings in regard to hazard identification of C60, carbon nanotubes, quantum dots, and 
nanometals will be introduced.  
 
5.1.1 C60 
Studies on C60 can be divided into three categories: 1) studies on C60 suspended 
by sonication or suspended in various solvents, 2) studies on hydroxylated C60 and 3) 
studies on functionalized C60. The number of in vivo toxicity studies is limited for all 
three categories. Gharbi et al. (2005) and Mori et al. (2006) observed no acute or 
subacute effects in rats exposed to C60 in a dose of 2 g/kg body weight (bw) 14 and 21 
days post exposure, respectively. Sayes et al. (2007a), however, did observe an increase 
in the percentages/numbers of Bronchoalveolar lavage (BAL)-recovered neutrophils 
(i.e. white blood cells) after intratracheally instillation of C60 and hydroxylated C60 i.e. 
C60(OH)24  just 1 day post-exposure. Sayes et al. (2007a) also observed a significant 
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increase in lipid peroxidation values and an increase in level of glutathione (GSH), after 
1 week. Lai et al. (2000) also observed a significant increase in lipid peroxidation 
products after intravenous administration of 1 mg C60(OH)18 per kg into male mongrel 
dogs previously induced with infusion/reperfusion injury. In contrast to Sayes et al. 
(2007a), Lai et al. (2000) observed a decrease in the GSH level in intestinal tissue. In 
one of the only studies so far investigating the embryo-/fetotoxicity on nanoparticles, 
Tsuchiya et al. (1995) observed shrunken membrane and narrow blood vessels on the 
yolk sac on 11 day pregnant mice and embryo death 18 hours (h) after intraperitoneal 
(i.p.) injection of between 25-137 mg C60 per kg.  
Adverse effects of functionalized C60 have been observed as well for instance by 
Chen et al. (1998) and Yamago et al. (1995). Chen et al. (1998) observed a LD50 of 600 
mg C60((CH2)4SO2Na)4-6/kg bw in female rats after intraperitoneal (i.p.) administration 
of between 0 and 2,500 mg/kg bw for 2 weeks. Whereas Yamago et al. (1995) observed 
symptoms of discomfort and weight loss in female mice after a single intraperitoneal 
injection of between 200-500 mg/ per kg.  
The cytotoxic effects of C60 have been studied extensively in vitro using a 
number of different cell strains, different test procedures including a range of different 
solvents to get C60 into suspension. Adelman et al. (1994) observed a reduction of the 
viability of bovine alveolar macrophages compared to control after exposure to 
sonicated C60 along with increased levels of cytokine mediators of inflammation (i.e. 
TNF, IL-6 and IL-8) whereas Baierl et al. (1996) and Porter et al. (2006) found that C60 
and raw soot was not toxic towards bovine- and human alveolar macrophages. The 
alveolar macrophage serves as the first line of cellular defense against respiratory 
pathogens (Rubins 2003) and hence studies reporting on the effects on alveolar 
macrophages are of special interests. 
Studies on the cytotoxicity of C60 towards cancer cell are ambiguities and while 
some have reported observing no signs of cytotoxicity of any kind after exposure to 
fairly high concentrations of C60, suspended in toluene, methanol and by sonication 
(Baierl et al. 1996, Levi et al. 2006), others do observe cytotoxicity of C60 suspended in 
tetrahydrofuran (THF) (Burlaka et al. 2004, Isakovic et al. 2006a, b). However, these 
studies are hard to interpret since they often use different transformed and/or damaged 
cell strains and different ways of suspending C60 – some even consider the cytotoxicity 
of C60 under the influence of light. 
Surface chemistry has been found to have an important influence on the toxicity 
of C60. Dose-dependent cytotoxicity of hydroxylated C60 and functionalized C60 has 
been observed for instance by Yamawaki and Iwai (2006) who observed a dose-
dependent decrease in cell density and lactate dehydrogenase (LDH) release in human 
umbilical vein endothelial cells cavity after exposure to C60(OH)24. Sayes et al. (2004) 
found that the toxicity of C60 towards human skin fibroblasts and liver carcinoma cells 
varied by seven orders of magnitude depending on the number of functional groups. 
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Aggregates of C60 were found to be substantially more toxic than highly soluble 
derivatives such as C3-, Na+2-3[C60O7-9(OH)12-15](2-3)-, and C60(OH)24. Rouse et 
al. (2006)  observed a dose-dependent decrease in the viability of human epidermeal 
keratinocytes after exposure to C60-phenylalanine while exposing HeLa cells to di-, tri-, 
quadrimalonic acid C60 was observed by Yang et al. (2002) to cause irradiation- and 
dose-dependent cytotoxicity.  
A number of studies also report finding no cytotoxic effects on macrophages, 
human keratinocytes, human skin and lung MC and PBB cells, and human fibroblasts 
cells after exposure to C60((CH2)4SO3Na)4-6, C60[C(COOH)2], Polyhydroxy C60, and N-
ethyl-polyamino C60 (Chen et al. 1997, Fumelli et al. 2000, Ryan et al. 2007). 
A number of studies have reported hydrolated C60 being able to reduced cell and 
neuronal death induced by: Doxorubicin (Bogdanovic et al. 2004), sodium nitroprusside 
(SNP) and H2O2 (Chen et al. 2004), NMDA, amino-3-hydroxy-5-methyl-4-isxazole 
propionic acid or kainite (Dugan et al. 1996), iron (Lin et al. 1999), serum (Lu et al. 
1998), UVB-irradiation (Xiao et al. 2005). Others have reported that glutathione, 
ascorbic acid and -tocopherol were capable of inhibiting membrane damage induced 
by hydroxylated C60 (Kamat et al. 2000). 
 A number studies on the environmental effects of C60 have been done as well. 
Oberdörster (2004) observed significant increase in lipid peroxidation of the brain of 
juvenile largemouth bass after exposure to uncoated fullerenes (99.5%) in 
concentrations of 0.5 and 1 ppm after exposure for 48 h. The C60 were dissolved in THF 
which have since then led to some discussion about whether C60 or the THF was 
responsible for the effects observed (Zhu et al. 2006, Henry et al. 2007).  
Henry et al. (2007) compared the effect on larval zebrafish Danio rerio of 1) 
99.5% C60 that had been prepared in water through stirring and sonication and 2) 99.5% 
C60 that had been dissolved in THF. Henry et al. (2007) observed no affect on the 
survival of larval zebrafish Danio rerio after exposure to stirred and sonicated C60 in 
concentrations up to 25% vol/vol for 72 hours. No death was observed in zebrafish 
Danio rerio < 5% vol/vol with LC50 = 3.1% (95% CI, 2.3–4.2%) for C60 dissolved in 
THF whereas lethal effects were observed within 60 min. above > 5% vol/vol, in 
addition to arched backs, severe yolk-sac and pericardial edema. Henry et al. (2007) 
also observed significant changes in expression of 271 genes compared to only 10 for 
stirred and sonicated C60. 
Zhu et al. (2006) compared the ecotoxicity on Daphnia magna of hydroxylated 
C60 with C60 dissolved in THF and found an LC50 > 35 ppm for hydroxylated C60 after 
48 hours compared to LC50 = 0.8 ppm for the THF-dissolved C60. 100% mortality was 
furthermore observed in fathead minnow after exposure to 0.5 ppm THF-dissolved C60 
for 6-18 hours, whereas no obvious physical effects were observed in fathead minnow 
after exposure to 0.5 ppm for 48 hours. Elevated lipid peroxidation was, however, 
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observed in the brain and gill along with increased expression of CYP2 family isozymes 
in the liver (Zhu et al. 2006, Oberdörster et al. 2006).  
Lovern and Klaper (2006) also compared sonicated C60 with C60 dissolved in 
THF.  Despite a great variation in mortality in Daphnia magna, they reported observing 
a LC50 of 7.9 ppm for sonicated C60. The lowest- and no observed effect concentration 
(LOEC and NOEC) was reported to be 0.45 ppm and 0.18 ppm, respectively. For C60 
dissolved in THF, a dose-dependent increase in mortality was observed after 48 hours, 
and LC50, LOEC, and NOEC was found to be sustainably lower i.e. 460, 260 and 180 
ppb, respectively. A number of behavioral changes have been reported as well. For C60 
dissolved in THF, Lovern et al. (2007) observed a significant increase in hopping rate, 
heart rate as well and the number of cycles per minute in appendage movement 
compared to control and 30 nm TiO2 after exposure to 260 ppb. 
In a long-term study Oberdörster et al. (2006) investigated the effect of 
hydroxylated C60 on the reproduction and survival rate of Daphnia magna and observed 
an increased cumulative mortality and significant delay in molting and reduced 
offspring after exposure to 1-5 ppm for 21 days.  
The hypothesis that C60 could act as a vector for the transport of other toxic 
chemicals has also been investigated. Baun et al. (2008) investigated whether C60 
affected the ecotoxic effects of known environmental pollutants such as phenanthrene 
and pentachlorophenol. It was found that the toxicity of phenanthrene was increased 
towards algae and Daphnia magna following sorption to C60 aggregates. In contrast, 
Baun et al. (2008) found that the toxic effect of pentachlorophenol decreased when C60 
was added.  
The effect on various kinds of bacterial strains has also been tested. Chiron et al. 
(2000) tested micronized C60 and observed no effect on microbial growth of 22 
collection strains including 6 strains of S. typhimurium, 5 strains of E. coli, and 2 strains 
of P. aeruginosa, S. aureus and L. monocytogenes (43.2 μg/mL). Babynin et al. (2002) 
found that the occurrence of mutations in S. typhimurium strain BA13 depends on the 
type of molecular group with which fullerene interacts whereas Fortner et al. (2005) 
observed that bacteria growth was media dependent. No growth was observed for either 
E. coli DH5 or B. subtilis CB315 exposed to > 0.4 mg/L C60 at pH= 7 under anaerobic 
or aerobic conditions using a Minimal Davis media. When using a Luria broth media, 
growth was observed when exposed to  2.5 mg/L. For C60 suspended in THF, Lyon et 
al. (2005, 2006) observed minimal inhibition concentrations of 0.5-1 mg/L and 1.5-3 
mg/L for E. coli and B. subtilis, respectively. Similar observations have been reported 
for various functionalized C60 (Tsao 2002, Mashino et al. 2003a, b, Tegos et al. 2005, 
Fang et al. 2007, Tang et al. 2007). 
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5.1.2 Carbon nanotubes  
 A number of studies have been done on the cytotoxicity of single-walled carbon 
nanotubes (SWCNTs). Cui et al. (2005) observed a dose-and time dependent inhibition 
of cell proliferation, and a decrease in cell adhesive ability in human embryo kidney 293 
cells after exposure to SWCNT in concentrations between 0.78125-200 g/mL for up to 
5 days. Shvedova et al. (2003) observed oxidative stress and cellular toxicity towards 
human epidermal keratinocytes (HaCAT), after 2 to 18 hours exposure to unrefined 
SWCNT (30% iron) in concentrations ranging from 0.6-0.24 mg/mL. This lead to 
speculation about whether adverse effects observed were caused by SCWNTs or iron 
residues.  
 Sayes et al. (2006a) found that cytotoxicity towards human dermal fibroblasts 
was dependent on the density of surface functionalization. Underivatized SWCNT was 
the most cytotoxic whereas a concentration dependent decrease in the viability of 
fibroblasts was observed for SWCNT functionalized with phenyl-SO3H, phenyl-
(COOH)2 and phenyl-SO3Na. This decrease did however not exceeding 50%.  
Lam et al. (2004) tested SWCNT of different purity, i.e. raw and purified 
nanotubes containing (29.6% and 2.14% Fe) and nickel-containing nanotubes (25.99% 
Ni). Lam et al. (2004) exposed mice to concentrations between 0 and 0.5 mg in 
durations of 7 and 90 days and found that all nanotubes induced dose-dependent 
granulomas and interstitial inflammation. The fact that purified nanotubes produced 
prominent granulomas indicates that nanotubes – and not the residue metals – are the 
cause of these lesions. The results by Lam were supported by observations made by 
Warheit et al. (2004) who also observed pulmonary grandulomas in rats after exposure 
to SWCNT soot (5% Ni and Co) in concentrations of 1 and 5 mg/kg for time durations 
of 24 hours up to 3 months. However, effects observed by Warheit et al. (2004) were 
non-dose dependent in contrast to Lam et al. (2004). Absence of pulmonary biomarkers 
suggests a potentially new mechanism of pulmonary toxicity and injury induced 
(Warheit et al. 2004).  
The number of studies reporting on the toxicity of multi-walled carbon 
nanotubes (MWCNTs) is far less, compared to SWCNTs. Carrero-Sanchez et al. (2006) 
observed lethal effects of 30, 60, and 90% in male inbred CD1 mice after intratracheal 
administration of a single dose of 1, 2.5, and 5 mg/kg along with signs of pulmonary 
distress, mainly dyspnea. Multiple granulomas were observed in the lung interstitium 
and globet cell hyperplasia after 15 d (50-150 μL/ 24 h-30 days post treatment). Muller 
et al. (2005) observed dose-dependent increase in LDH release in female Sprague-
Dawley rats after intratracheal instillation which was more marked in the ground 
MWCNTs (0.5-5mg/60d) than in MWCNTs.  
Recently, Pollard et al. (2008) compared the toxicity of four kinds of MWCNT 
of various diameters, lengths, shape and chemical composition by exposing the 
mesothelial lining of the body cavity of three mice with 50 mg MWCNT for 24 hours or 
 35
7 days. This method was used as a surrogate for the mesothelial lining of the chest 
cavity. It was found that long MWCNTs “produced length dependent inflammation, 
FBGCs and granulomas that were qualitatively and quantitatively similar to the foreign 
body inflammatory response caused by long asbestos”. Only the long MWCNTs caused 
significant increase in polymorphonuclear leukocytes or protein exudation. The short 
MWCNTs failed to cause any significant inflammation at 1 day or giant cell formation 
at 7 days. Pollard et al. (2008) also found that water-soluble components of MWCNT 
did not produce significant inflammatory effects 24 hours after injection, which rules 
out that residue metals were the cause of the observed effects such as others previously 
had speculated on the basis on in vitro studies (Shvedova et al. 2005, Kagan et al. 
2006). 
Plenty of cytotoxicity tests have been carried out on MWCNTs. Bottini et al. 
(2006) for instance, found that MWCNT was more cytotoxic when oxized towards 
viability of Jurkat T leukemia cells whereas Clopek et al. (2006) and Monteriro-Riviere 
et al. (2005) observed a decrease of the viability of human osteoblastic lines and human 
epidermal keratinocytes.  
Similar to observations made on the ecotoxiciy of C60, Roberts et al. (2007) 
observed peak survival in Daphnia magna at 0.5 mg/L whereas mortality of 20% and 
100% were observed at 10 and 20 mg/L, respectively, after 96 hours of exposure to 0-20 
mg of 85% SWCNT coated with lysophophatidylcholine. Smith et al. (2007) tested the 
ecotoxicity of SWCNT dissolved through a combination of sodium dodecyl (SDS) and 
sonication and they observed a dose-dependent rise in ventilation rate, gill pathologies 
(oedema, altered mucocytes, hyperplasia), and mucus secretion with SWCNT 
precipitation on the gill mucus of juvenile rainbow trout. They also observed dose-
dependent changes in brain and gill Zn or Cu, partly attributed SDS, a significant 
increase in Na+K+-ATPase activity in the gills and intestine, a significant dose-
dependent decrease in thiobarbituric acid reactive substances (TBARS), especially in 
the gill, brain and liver, and a significant increase in the total glutathione levels in the 
gills (28%) and livers (18%), compared to the solvent control (15 mg/L SDS). TBARS 
are indicators of lipid peroxidation and oxidative stress. Finally, Smith et al. (2007) 
observed increasing aggressive behavior, possible aneurisms or swellings on the ventral 
surface of the cerebellum in the brain and apoptotic bodies and cells in abnormal 
nuclear division in liver cells.  
Cheng et al. (2007) observed significantly delayed hatching of zebrafish (Danio 
rerio) embryos from the blastula period following exposure to 120-360 mg SWCNT/L 
for 4-96 hours whereas carbon black and double walled carbon nanotubes had no 
influence on hatching at either of the tested concentrations i.e. 20-360 mg/L. The 
hatching delay observed for SWCNT did not influence the hatching success rate and 
survival of the embryos exposed to between 20-360 mg/L up to 96 hours 
postfertilization.  
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Templeton et al. (2006) compared “As prepared” SWCNT with electropho-
rectically purified SWCNT and the fluorescent fraction of nanocarbon byproducts. 
Templeton et al. (2006) observed an average cumulative life-cycle mortality of 13 ± 
4%, while mean life-cycle mortalities of 12 ± 3, 19 ± 2, 21 ± 3, and 36 ± 11%  were 
observed for 0.58, 0.97, 1.6, and 10 mg/L. Exposure to 10 mg/L showed: 1) 
significantly increased mortalities for the naupliar stage and cumulative life-cycle, 2) a 
dramatically reduced development success to 51% for the nauplius to copepodite 
window, 89% for the copepodite to adult window, and 34% overall for the nauplius to 
adult period, and 3) a significantly depressed fertilization rate averaging only 64 ± 13%. 
They also observed that exposure to 1.6 mg/L caused a significantly increase in 
development rate of 1 day faster, whereas a 6 day significant delay was seen for 10 
mg/L. For the electrophorectically purified SWCNT, Templeton et al. (2006) observed a 
naupliar, copepoddite, and adult-stage mortality of 13 ± 2, 3 ± 0, and 0 ± 0%, 
respectively, after 28 d and a significant 1 day delay in development rate at 1.6 mg/L 
after exposure to between 0.58-10 mg/L. For the fluorescent fraction of nanocarbon 
byproducts, the cumulative life-stage mortality averaged 10 ± 3%. For the two highest 
concentrations tested (i.e. 1.6 and 10 mg /L), nauplius-to-adult stage mortalities were 
increased with average full life-cycle mortalities of 81 ± 7% whereas development 
success in treatments ranged between 81 and 95%. For the copepodite-to-adult stage 
transition, the three highest exposures of 0.97, 1.6 and 10 mg/L resulted in significantly 
reduced development success, whereas this was the case for all concentrations when 
considering the full life-cycle development success from the nauplius-to-adult stage.  
 
5.1.3 Quantum dots 
The toxicity of quantum dots (QDs) has been found to differ among others 
depending on the constituting metals, size, metal ratio, surface charge and coating of the 
QDs. Larson et al. (2003), for instance, observed no ill effects on mice after intravenous 
injection of CdSe/ZnS (~ 1 M and 20 nM), and a number of studies have reported 
observing no effect on quantum dots such as CdSe and CdSe/ZnS on various cell lines 
(Chen and Gerion 2004, Chan et al. 2006, Delehanty et al. 2006). Delehanty et al. 
(2006) did, however, observe dose-dependent cell proliferation for CdSe/ZnS after 
incubation of COS-1 or HEK 293T/17 cell lines, just as Zhang et al. (2007) have 
reported observing in human hepatoma HepG2 cells for CdTe. 
The cytotoxicity of QDs was found to be influenced by the exposure to light and 
temperature dependent. Green and Howman (2005), for instance, observed 56% 
damaged DNA after incubation and exposure to UV light for 0-60 min. vs. 29% when 
incubated in the dark for CdSe/Zn. Whereas Chang et al. (2006) found that CdSe/CdS 
was cytotoxicity to cancer cells at 37 ºC, but not at 4 ºC. Quantum dots are often coated 
in order to improve their biocompability and to reduce their toxicity (Hardman, 2006). 
Adverse cytotoxic effects have been reported on in mouse lymphocytes after exposure 
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to CdSe/ZnS coated with albumin fraction V (Hoshino et al. 2004). Kirchner et al. 
(2005) and Lovríc et al. (2005) observed significant decrease in cell metallic activity 
and marked cytotoxicity in NRK fibroblasts, MDA-MB-435S breast cancer cells, 
Chinese ovary cells (CHO), rat basophil leukemia (RBL) cells and rat 
pheochromocytoma cells (PC12) and N9 murine microglial cells for not only QD of 
different sizes coated with MPA but also of dots coated with Cysteamine hydrochloride. 
Uncoated CdTe QDs were cytotoxic at 1 g/mL. Derfus et al. (2004) found that the 
cytotoxicity of CdSe coated with TOPO could be reduced by capping them with ZnS, 
MAA (mercaptoacetic acid) and bovine serum albumin (BSA) whereas Lovríc et al. 
(2005) also observed that cytotoxicity was more pronounced with smaller positively 
charged QDs (2.2 ± 0.1 nm) than with larger equally charged QDs (5.2 ±0.1 nm) at 
equal concentrations. In contrast Jaiswal et al. (2003) found that CdSe/ZnS coated with 
DHLA had no effect on mammalian cells and Ballou et al. (2004) observed no signs of 
necrosis or decreased viability of mice after injection of QD coated with amphiphilic 
polyacrylic acid polymer and PEG-amine groups at QD concentrations of 20 pmol QD/g 
animal weight. 
Only a limited number of studies have been done of the ecotoxicity of QDs. 
Dubertret et al. (2002) observed some abnormalities in cell size, cell death, and cell 
movement after injected in frog embryos at higher concentrations (> 5×10 QDs per cell) 
10-15 nm CdSe/ZnS quantum dots coated with n-poly(ethylene glycol) 
phosphatidylethanolamine and phosphatidylcholine. 
 
5.1.4 Nanometals 
A number of different nanometals have been tested  in (eco)toxicity tests and in 
the following the findings regarding nano- Titanium dioxide, Zink, Silicon dioxide and 
Iron  oxide will be presented.  
 
Titanium dioxide 
Various effects have been observed in various strains of rodents after exposure 
to TiO2 and several studies report differences in the responses for TiO2 particles smaller 
than 100 nm compared to those found for larger particles.   
After long-term and daily exposure Oberdörster et al. (2004) observed 
progressive increase in total cells lavaged in rats and a significantly prolonged 
pulmonary retention and sustained impairment of alveolar macrophages for 20 nm 
particles (23.5 mg/m3) compared to the 250 nm particles (23.5 mg/m3). Ferin et al. 
(1992) and Baggs et al. (1997) also observed greater alveolar epithelial thickness and 
fibrosis in rats for 20 nm particles than for 250 nm particles, whereas Wang et al. 
(2007a) found a significantly higher level in the liver coefficients in female mice after a 
single dose oral administration of 80 and 25 nm particles compared to control and 155 
nm particles.  
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When comparing anatase TiO2 particles of 20 and 250 nm Oberdörster (2000) 
found that the former generated a much greater pulmonary-inflammatory response in 
rats after exposure to equal mass doses. When the dose is expressed as a function of 
mass and surface particle number it showed huge differences in the dose-response curve 
of the two materials, but when expressed in terms of particle surface area, both forms of 
TiO2 followed a similar dose-response curve. Donaldson et al. (2002) reported 
observing a similar correlation for carbon black, when studying the ability of nano- and 
micron particles to cause inflammatory effect in rats (Donaldson et al. 2002). Warheit et 
al. (2006) and Sayes et al. (2007b) reported, however, not to have observed any 
association with surface area when evaluating biological response in rats after exposure 
to nano-sized TiO2, SiO2 and other particles.  
A number of factors have been hypothesized to influence the toxicity of TiO2 
besides surface area. These include crystalline structure and shape and exposure route 
(e.g. intratracheal vs. oral vs. inhalation). Oberdörster et al. (1992) observed that anatase 
and rutile TiO2 caused different responses in rats after intratracheal instillation. For 
anatase TiO2, a significant increase in total lavagable cells, polymorphonuclear 
leukocytes (PMN) and total protein content was observed whereas a low level of PMN 
response was observed for rutile particles.  
Warheit et al. (2007a) observed no difference in the effects caused by spherical 
dots versus nanorods of TiO2 – both caused a short-lived 24 hours post-exposure, 
increase in the percentages/numbers of BAL-recovered neutrophils, BAL fluid LDH 
and BAL fluid micro-protein in rats after intratracheally instillation of 5 mg/kg after 24 
hours and 3 months post-exposure. Warheit et al. (2007b) furthermore observed that a 
temporary increase in percentages of BAL-recovered neutrophils for  98 and 88 wt% 
TiO2 24 hours after intratracheal instillation. For 100% wt, inflammation was still 
evident after 3 months for rats exposed to 5 mg/kg.  
The influence of coatings has been investigated as well by Höhr et al. (2002) 
who observed a lower non-significant total cell number and influx of neutrophils (PMN) 
in female rats after intratracheal instillation of 1 mg coated particles compared to 
untreated particles. No difference was observed with 6 mg or surface area > 600 cm2. 
Questions have been raised about the biological relevance of intratracheal 
instillation since it bypasses upper respiratory tract defenses and does not deposit 
particles evenly in the lung similar to what would be observed after inhalation (Oiser et 
al. 1997). Observations made by Ferin et al. (1991) might support this argument. They 
observed that intratracheal instillation of 20 nm particles caused a more pronounced 
effect in rats (i.e. increased number of leukocytes) compared to inhalation. Osier and 
Oberdörster (1997) contradict these findings in the sense that they observed 
significantly elevated levels of total protein following inhalation compared to 
intratracheal instillation. 
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The cytotoxicity of TiO2 has been found to be dependent on crystalline structure, 
size and purity as well. Sayes et al. (2006b) observed a time-dependent decrease in 
human dermal fibroblasts (HDF) for anatase TiO2 (30 μg/mL/1-48 h) and found a LC50 
= 3.6 μg/mL, but for rutile TiO2, the LC50 was substantially higher and equal to 550 
μg/mL. with LC50 of anatase/rutile TiO2 falling between the two.  
Zhu et al. (2006) observed a more severe toxic effect (LC50= 100 μg/mL) and 
cell apoptosis on Chinese hamster ovary tumor cells after 24 hours, whereas growth 
inhibition was the only effect observed in human kidney epithelium 293T cells (LC50= 
300 μg/mL). Wang et al. (2007b) observed a time- and dose-dependent decrease in the 
viability of WIL2-NS human lymphoblastoid cells ranging from 2-62% (0-130 
μg/mL/6-48 h) whereas Rahman et al. (2006) observed significant increase in 
micronuclei in Syrian hamster embryo cells after treatment with 1.0 g/mL  20 nm 
particles whereas > 200 nm particles had no effect (0.5-10 g/mL/12-72h).  
Limbach et al. (2007) found promoted increase in reactive oxygen species 
(ROS) in human lung epithelial A459 cells that increased with the purity of the particles 
(30 μg/mL/4 h). This observation was supported by Long et al. (2006) who observed a 
rapid (< 5 min) and sustained (120 min) release of ROS at non-cytotoxic concentrations 
(2.5-120 ppm/1-18 h) in BV2 brain microglia.  
Vileno et al. (2007) observed the generation of ROS in human skin fibroblasts 
CCL-110 as well as cellular stiffness under illumination with UVA (8 and 20 mW/cm2 
for up to 180 s) whereas no cellular stiffness was observed without illumination.  
The UV-reactive of TiO2 has been a subject of several studies and although 
Uchino et al. (2002) and Gurr et al. (2005) found no additional effect of photoactivation 
against human bronchial epithelial BEAS-2B-cells and Chinese hamster ovary cells, 
evidence indicates that the cytotoxicity of TiO2 is influenced by UV-irradiation. Cai et 
al. (1991, 1992) and Huang et al. (59) observed a survival rate higher than 90% in HeLa 
cells and U937 cells exposed to more than 360 μg/cm-3 for 24 hours but observed 75-
90% killing of cells after 10 min. exposure of UV light. Sayes et al. (2006b) found that 
UV illumination (10 W/cm2) of TiO2 made cell death increase by 20%. Anatase TiO2 
produced a high LDH release in cells which increased when exposed to UV light and 
decreased mitochondrial activity and enhanced IL-8 in both HDF and A549 cells. 
Anatase/rutile TiO2 produced a biological response less than that of anatase, but greater 
than rutile TiO2. 
Ivankovic et al. (2003) observed that the survival fraction for squamous 
Carcinoma SCVII cells not only differed between highly-dispersed and lowly-dispersed, 
but also differed when exposed to UV-irradiation. The cytotoxicity was higher for 
anatase and brookite TiO2 particles of different sizes after being irradiated with 7-8 mV 
cm-2 for 10 min. which again did not differ much for iron-doped anatase TiO2 
nanoparticles. Iron-doped Anatase + rutile nanoparticles of different sizes were, 
however, found to be sustainably less toxic. Cytotoxicity differed most between highly 
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dispersed and low dispersed nanoparticles. For 20 nm anatase/rutile TiO2, survival 
fraction ranged between 0.768 (highly-dispersed) and 0.366 (lowly-dispersed) whereas 
it was 0.970 (highly-dispersed) and 0.418 (lowly-dispersed) for 17 nm iron-doped 
anatase/rutile TiO2. 
The effects of TiO2 and irradiation on bacteria have also been studied. Maness et 
al. (1999) observed that E. coli K-12 cell death was dependent on cell concentration 
(9.1 × 102-5×108) after 30 min. irradiation (8 W/m) (0.1-1 mg/mL), whereas Rincón and 
Pulgarin (2003) found that cell survival was time-dependent in the presence of sunlight. 
Nakagawa et al. (1997), however, observed no significant increase in the frequency of 
revertant colonies in S. typhimurium strain TA100, TA98 and TA102 exposed to light 
(0-5 J/cm2).  
Finally, in a (eco)toxicity study on Daphnia magna, Lovern and Klaper (2006) 
compared 30 nm size TiO2 nanoparticles with TiO2 of the same size dissolved in THF 
and sonicated 100-500 TiO2 nanoparticles in a 48 hour immobilization test. For TiO2, a 
dose-dependent increase in mortality in D. magna (0-10 ppm) was observed and LC50 
was estimated to be 5.5 ppm with LOEC and NOEC being equal to 2.0 and 1.0 ppm, 
respectively. No significant difference was observed in D. magna exposed to TiO2 
prepared with THF and TiO2 alone whereas the mortality varied across concentrations 
ranging from (50 ppm-500 ppm and never exceeded 10% for the sonicated TiO2. Zhang 
et al. (2007) investigated the effect of exposing carp to a combination of TiO2 and 
cadmium salts and observed a 2.5-fold increase in cadmium accumulatation (Zhang et 
al. 2007). 
 
Zink 
In one of the only studies in which humans have been exposed directly to 
nanoparticles, Beckett et al. (2005) reported observing no difference in 6 women and 6 
men 24 hours after exposure to a total of 500 μg Zn/m3 over the course of 3 times 2 
hours over 3 d.  On the other hand Gordon et al. (1992) reported observing symptoms 
such as fever, chills, sore throat, chest tightness and headache in 4 human volunteers 
after exposure of 5 mg/m3 for 2 h. They also observed a significant increase in total 
cells, lactate dehydrogenase (LDH), -glucuronidase, and protein content in male 
Hartley guinea pigs and Fisher 344 rats after 4 and 24 hours post-nose-only exposure of 
5 mg/m3. Additionally, they found that -glucuronidase was decreased in New Zealand 
rabbits exposed to 5.0 mg/m3 after 2 hours, whereas no increase was observed in total 
cells, LDH, and protein content. Wang et al. (2006a) observed some death and severe 
symptoms of lethargy, anorexia, vomiting, diarrhea, and loss of body weight in mice 
after gastrointestinally administration, whereas limited effect was observed for micro-
Zn.  
Sayes et al. (2007b) observed an increase in the production of LDH levels in 
immortalized rat lung epithelial cells after 1 hour exposure to Zn at 520 μg/cm2 and 
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LDH levels were observed to be increased at concentrations  0.052 and 0.52 μg/cm2 
after 4 and 24 h, respectively, but not after 48 hours and no increase in LDH levels were 
observed in primary rat alveolar macrophages.  
Gojova et al. (2007) observed a 20 and 50% cell death at 10 and 50 g ZnO/mL 
respectively and viability was observed to be 89 ± 1% and 82 ± 3% after 4 hours. Long 
et al. (2006) observed 15-50% cell death after exposure to concentrations in the same 
range, i.e. 50-100 μg/mL. As with TiO2, the UV reactivity of ZnO has been 
investigated. Dufour et al. (2006) observed that the dose needed to reach 40–60% 
concentration-dependent cytotoxicity in CHO cells decreased if cells were exposed to 
particles and irradiated simultaneously or had been pre-irradiated. Finally, Brayner et al. 
(2006) reported observing 15% growth inhibition E. coli strain MG1655 in a bacterial 
test on ZnO2.  
 
Silicon dioxide 
In the literature, the toxicity of TiO2 has often been compared to Si and SiO2. 
When comparing Si particles of different average sizes (i.e. 12, 50, 300, and 534 nm), 
Warheit et al. (2006) found a higher number of cells recovered by Bronchoalveolar 
lavage (BAL) from the lungs of rats after intratracheally instillation of 5 mg/kg 534 nm 
particles than with any of the other sizes of particles. For the 50 nm particles, a 
substantial lung inflammatory response was observed in rats at 24 hours post-exposure 
followed by a 15–20% increase in polymorphonuclear leukocytes 3 months post-
exposure, whereas 534 nm particles produced persistent pulmonary inflammatory 
responses, with the 5 mg/kg producing > 40% neutrophils after 3 months post-exposure. 
300 nm particles produced a reduced inflammatory response. A significant greater 
pulmonary inflammatory response in the lungs of rats was also reported for 1.6 m 
particles compared to 50 nm particles (Warheit et al. 2007b).  
 Cytotoxic effects have been reported as well. Chen and Mikecz (2005) observed 
a significant inhibition in replication and transcription in human epithelial HEp-2 cells 
for 70 nm particles after exposure to 25 μg SiO2/mL for 24 h. Lin et al. (2006) tested 
amorphous SiO2 and observed a dose- and time dependent decrease in the viability of 
human bronchoalveolar carcinoma A549 cells. For 15 nm particles cell numbers 
decreased to 82.8%, 67.1%, and 54.6% for 10, 50, and 100 g/mL respectively after 72 
hours and there was no significant difference between 15 and 46 nm particles.  
Various kinds of coatings – including succinic acid (Jovanovic et al. 2006), 
dimethylamino groups (Bertazza et al. 2006), chitosan (Chang et al. 2007) and TiO2, 
Mn, Cu, Fe (Limbach et al. 2007) – have been reported to affect the hemolytic activity 
of red blood cells, ROS generation in human lung epithelial A459 cells and the viability 
of human oesophageal squamous cell carcinoma KYSE-510 and various kinds of human 
skin fibroblast human epithelial cells. 
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Iron oxide 
Only a limited number of studies have been done on nano-Fe in vivo. For 
instance Brusentov et al. (2004) reported LD50 of crystal -Fe2O3 and FeO coated with 
Dextran to be 5 g/kg after intravenous and intraperitoneal injection into mice. Bourrinet 
et al. (2006) studied the effects of Dextran coated Fe3O4 as well and reported observing 
a slightly significant increase in aortic blood flow at 13 mg/kg in rats and swollen snout 
and/or paws, dark body areas, labored respiration, and red crust around the nose and 
loss in body weight after intravenous bolus administration. Bourrinet et al. (2006) also 
reported observing ataxia, hypoactivity, exophthalmos, emesis, salivation, lacrimation, 
discolored and mucoid feces, injected sclera, and yellow eyes in dogs after a single-dose 
exposure of 20 and 200 mg Fe/kg through intravenous bolus administration and a 
significant increase in fetal skeletal malformations in rats and rabbits. Zhou et al. (2003) 
observed a significant elevation in total protein within the lavage fluid in male Sprague 
Dawley rats after inhalation of -Fe2O3 for 6 hours per day for 3 days. Gojova et al 
(2007) observed no increase in ICAM-1, IL-8, or MCP-1 mRNA levels in human aortic 
endothelial cells and viability was observed to be 88 ± 4% and 92 ± 3% at 10 and 50 g 
Fe2O3/mL, respectively after exposure of 4 hours. Limbach et al. (2007) tested Fe2O3 of 
different purity and observed no increase in ROS level in human lung epithelial A459 
cells (30 μg/mL/4 h). Pisanic et al. (2007) and Auffan et al. (2006) observed that Fe2O3 
and Fe2O3 coated with DMSA caused a significant dose-dependent decrease in 
viability and cell detachment in rats’ PC12 pheochromocytoma clonal cells, and in 
human dermal fibroblasts. Gupta and Curtis (2004) and Gupta and Gupta (2005) 
observed no cytotoxicity or increase in the number of attached InfinityTM telomerase-
immortalized primary human fibroblasts cells for Fe3O4 coated with 
Poly(ethyleneglycol) (PEG) and Pullulan in concentrations up to 20 mg/mL. They did, 
however, observe an up to 64% significant decrease in the number of attached cells for 
uncoated particles exposed to just 0.1 mg/mL. Hilger et al. (2003) observed a time-
dependent decrease in the survival of human adenocarcinoma cells (BT-20) for both 
positively and negatively charged Fe3O4 particles with sizes varying from 8 to 220 nm 
in pure form and with various forms of surface chemistry. On the other hand Cheng et 
al. (2005) and Yu et al. (2006) observed limited and no difference in the viability of 
Cos-7 monkey kidney cells, human breast cancer SK-BR-3 cells and human dermal 
fibroblasts. Muller et al. (2007) only observed slight 10% fluctuations in the viability of 
human monocyte macrophages for Fe3O4 coated with Dextran. 
 
Other metals 
Most studies performed explored the hazards of nano-TiO2, Zn, Si/SiO2 and Fe 
although adverse effects have been observed on rodents, guinea pigs, and cells for other 
nanometals including Cu, Ag, Au, Ni, Se, Mg, CdO, and CdCl2 (see Serita et al. 1999, 
Zhang et al. 2001, Casse et al. 2002, Alessandrini et al. 2003, Zhang et al. 2004, Berry 
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et al. 2003, 2004, Goodman et al. 2004, Jia and Chen 2005, Zhang et al. 2005, 
Bhattacharya et al. 2004, 2007, Connor et al. 2005,  Pernodet et al. 2006, Niidome et al. 
2006, Huff et al. 2007). Zhang et al. (2001), for instance, found the acute toxicity in 
mice of Se decrease 7-fold when coated with BSA. LD50 was found to be 113 and 15.7 
mg Se/kg bw respectively, whereas Cui et al. (27) observed severe toxicological effects 
and heavy injuries on kidney, liver and spleen after exposure via oral gavage to Cu, 
including that male mice seemed to suffer more than female mice. LD50 was reported by 
Cui et al. to be 413 (95% CI 305–560) mg/kg bw.   
Yang and Watts (2005) tested both pure 99.6% Al2O3  as well and various 
surface modifications of Al2O3 on the relative root growth (RRG) in Zea mays (corn), 
Glycine max (soybean), Brassica oleracea (cabbage), and Daucus carota (carrot). For 
pure 99.6% Al2O3 RRG was significantly (avg. p= 0.015) inhibited compared to control 
after exposure to 2 mg/mL for 24 h. The RRG of cucumber was found to be 1.24- and 
1.21-fold of that of Al2O3 particles alone for Al2O3 loaded with 10.0% and 100.0% 
monomolecular layer of Phen. No toxicity towards cucumber was observed in regard to 
root growth (2 mg/mL of Al2O3 nanoparticles loaded with 432.4% monomolecular layer 
of Phen). No detectable effect on root growth (avg. p = 0.84) in corn, soybean, cabbage, 
and carrot compared to control exposed to 2 mg/mL of Al2O3 loaded with 10.0% 
monomolecular layer of Phen for 24 hours. Recently, Seeger et al. (2008) tested the 
effects on willow trees after exposure to 25 and 100 nm TiO2-particles and reported 
observing no significant effect on growth, transpiration and water use efficiency in 
concentrations up to 100 mg/L after 2 weeks. Agglomeration and sedimentation of 
nanoparticles was observed to be more rapid in the presence of tree root.  
Microbial toxicity has been tested for a number of nanoparticles on a number of 
bacterial strains. The most studied is probably nano-Ag. Alt et al. (2004) observed a 
dose dependent antibacterial effect on S. epidermidis EDCC 5245, and methicillin-
resistant S. epidermidis ECCC 5130 and reported that bone cement with 1% nano-Ag 
completely inhibited proliferation of S. epidermidis EDCC 5245, methicillin-resistant S. 
epidermidis EDCC 5130 and methicillin-resistant S. aureus EDCC 5246. Baker et al. 
(2005) observed dose-dependent increase in antibacterial behavior against E. coli  (0-
0.114 mg/mL) whereas Morones et al. (2005) observed no significant growth above 75 
μg/mL in E. coli, V. cholera, P. aeruginosa and S. typhus (0-100 μg/mL/30 min.). Pal et 
al. (2007) found that the growth of E. coli ATCC 10536 was dependent on the shape of 
the nano-Ag and most outspoken for triangular and spherical particles for which 
significant and complete growth inhibition was observed. Some colonies were able to 
grow even in presence of 100 g rod shape Ag particles. Sondi et al. (2004) observed a 
70 and a 100% inhibition of growth in E. coli strain B at 10 and 50-60 μg Ag cm-3 
respectively in Luria broth medium. Thill et al. (2006) – for CeO2 nanoparticles – 
observed a concentration-dependent decrease in the percentage of E. coli bacteria 
colony forming units. 50% decrease was observed at 5 CeO2 ppm, however, the 
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presence of particles in the Luria broth growth medium did not influence the growth of 
the cells after 1-5 hours when exposed to 0.46-500 mg/L. Finally, Tang et al. (2007) 
observed no effect on E. coli K12 and S. oneidensis MR-1 after exposure to Au in 
concentration of up to 80 mg/L. 
 
5.2 Dose-response assessment 
According to the TGD a dose-response assessment involves “…an estimation of 
the relationship between dose, or level of exposure to a substance, and the incidence 
and severity of an effect” (European Commission JRC 2003).  
Several of the studies mentioned above have reported observing dose-response 
relationship. This goes for, especially, in vitro studies on among other C60, single- and 
mulitwalled carbon nanotubes, and various forms of nanometals. Normally, dose refers 
to ‘dose by mass’, however, based on the experiences gained in biological tests of 
nanoparticles, it has been suggested that biological activity of nanoparticles might not 
be mass-dependent, but dependent on physical and chemical properties not routinely 
considered in toxicity studies (Oberdörster et al. 2005b). For instance, Oberdörster et al. 
(1996, 2007) and Stoeger et al. (2006, 2007) found that the surface area of the 
nanoparticles is a better descriptor of the toxicity of low-soluble, low toxicity particles, 
whereas Wittmaack (2007a, b) found that the particle number worked best as dose 
metrics. Warheit et al. (2007a, b) found that toxicity was related to the number of 
functional groups in the surface of nanoparticles.  
However, it is still an open question which properties determine or influence the 
inherent hazards of nanoparticles partly due to the general lack of characterization of the 
nanoparticles tested (Hansen et al. 2007).  
Physical and chemical properties such as particle size, size distribution, number 
concentration, agglomeration state, shape, crystal structure, chemical composition, 
surface area, surface chemistry, surface charge, porosity, and method of synthesis are in 
the literature proposed as properties that need to be considered (Oberdörster et al. 
2005a, b, Lam et al. 2006, Warheit 2008). However, many of the proposed physical and 
chemical properties are overlapping, or are only applicable to nanoparticles and not to 
nanomaterials in general and/or are rarely reported on in eco(toxicological) studies. 
Table 1 summarizes the number of studies that reported different characteristics in 
percentage. The table shows that there is a large difference in which characteristics have 
been reported in the literature.  
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Table 1: The percentage of studies on nanoparticles that provide information on specific risk 
characteristics. See supporting information of Hansen et al. (2007) for references and data compilation. 
 No. of 
compounds
Chemical 
comp. 
Size Shape Crystal 
struc. 
Surface 
area 
Surface 
charge
Surface 
chem.. 
Solu-
bility 
Adhesion
CXX 210 100 17 8 2 6 7 4 7 - 
SWCNT 64 100 45 39 2 14 2 20 - 2 
MWCNT 39 100 56 33 8 23 - 5 - - 
QDs 73 100 71 10 - - 27 85 - - 
N-metals 275 100 96 39 24 33 17 25 4 - 
Others* 304 100 76 12 .3 12 30 26 2 - 
*) Others include polymers, in-organic nanoparticles, carbon black, and soot 
 
 The majority of all the studies report the chemical composition of the 
nanoparticles tested. C60 behaves neither as a simple molecule or as a bulk solid 
(Fortner et al. 2005), however only 17% of the studies testing the toxicity of C60 report 
the size distribution, and only 8% report on the shape of the aggregates of C60. The 
greater portion of the studies on SWCNT report on the surface chemistry, whereas 
almost none of the studies on C60 and MWCNT have done so. Surprisingly, only about 
half of the studies on SWCNT reported on the size even though the unique features of 
SWCNT vary with the diameter and length of the SWCNT. Furthermore, only one study 
reported the crystal structure for the SWCNT tested, although it is well known that 
several properties of the SWCNT depend on the crystal structure (i.e. armchair (n,n), 
zigzag (n,0), or choral (2n,n) SWCNT). And only one study reported the adhesion by 
which the nanomaterial is held together, although adhesion is important to the stability 
of the individual particles as well as aggregates of particles. In the case of quantum dots, 
for example, it has been reported that the shell protecting the toxic core of quantum dots 
can be degraded or broken down (Jordan et al. 1996, Berry et al. 2003, Derfus et al. 
2004). 
When estimating the hazard of nanomaterials – instead of just generating a 
laundry list of properties that one could imagine influences the (eco)toxicity of 
nanoparticles – Hansen et al. (2007) propose considering the information needed in 
order to describe a nanomaterial from a physical and chemical perspective. This would 
lead to the following properties as being important: 1) Chemical composition, 2) Size, 
3) Shape, 4) Crystal structure, 5) Surface area, 6) Surface chemistry, 7) Surface charge, 
8) Solubility, and 9) Adhesion – defined as the force by which the nanoparticles and its 
components are held together (Beck-Speier et al. 2001, Berry et al. 2004, Cheng 2004, 
Lockman et al. 2004, Nigavekar et al. 2004, Sayes et al. 2004, Baker et al. 2005, Martin 
et al. 2005, Fortner et al. 2005, Brunner et al. 2006). For reviews of methods for 
estimating these properties see for instance Tsuji et al. (2006), Maynard and Aitken 
(2007), and Powers et al. (2006). Recently, the Organisation for Economic Co-operation 
and Development (OECD) published a list of nanomaterials and endpoints selected for 
phase one of the OECD testing program adding additional properties such as dustiness, 
representative transmission electron microscopy (TEM) picture(s), and photocatalytic 
activity without making  clear how these should be measured or reported (OECD 2008).  
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Although so far, only a few studies have reported to have observed adverse 
effects of engineered nanoparticles on humans or the environment, a fair number of 
studies have been published on nanoparticles and cytotoxicity. The number of studies 
on mammalian toxicity is still limited and only a very limited number of studies address 
the ecotoxicity of nanoparticles. It is, however, important to notice that the vast majority 
of the 428 studies reviewed demonstrate some degree of adverse effects on tested 
animals or cell lines (Hansen et al. 2007). Endpoints reported on vary substantially and 
reading across and interpreting the results of the various studies is hard at the moment 
since nanomaterials tested differ substantially in regard to: 1) physical-chemical 
properties such as chemical composition and shape and 2) endpoints tested for and 
duration of exposure and methods (e.g. assays) and standards used (Hansen et al. 2007). 
Preliminary results, however, indicate that in vitro testing may not always predict 
hazards accurately whereas the number of large in vivo studies has been limited and 
difficult to reproduce (RCEP 2008, CCA 2008). For many nanoparticles it is not clear 
whether a threshold exists (by any metric) below which exposure ceases to cause 
adverse effects (Wittmaack 2007, Hansen et al. 2007, RCEP 2008). It is furthermore not 
clear whether the endpoints tested and reported on actually are the most sensitive or the 
most relevant, or whether new biological endpoints might show to be more relevant 
(RCEP 2008).  
Recently, an expert committee gathered by the Council of Canadian Academies 
(CCA 2008) argues that “…based on the current understanding of toxicological 
sciences, there are no new biological endpoints caused by the exposure to 
nanomaterials”. However, it cannot be ruled out that nanoparticles are harmful by some 
other paradigm not yet explored (Pollard et al. 2008, RCEP 2008). Most of the studies 
done so far follow a more or less traditional paradigm and one can hardly expect that 
new endpoints will spring from our current understanding and/or can be detected by 
using traditional toxicological methods (RCEP 2008).  
 
5.3 Exposure assessment 
Exposure is a key element in risk assessment of nanomaterials since it is a 
precondition for the potential toxicological and ecotoxicological effects to take place. If 
there is no exposure – there is no risk. According to the Technical Guidance Document 
exposure assessment involves “…an estimation of the concentrations/doses to which 
human populations (i.e. workers, consumers and man exposed indirectly via the 
environment) or environmental compartments (aquatic environment, terrestrial 
environment and air) are or may be exposed.” (European Commission JRC 2003a). 
Completing a full exposure assessment requires extensive knowledge about 
among others manufacturing conditions, level of production, industrial applications and 
uses, consumer products and behavior, and environmental fate and distribution.  
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Such detailed information is not available and so far no full exposure assessment 
has been published for any one or more nanomaterials. This may partly be due to 
difficulties in monitoring nanomaterial exposure in the workplace and the environment, 
and partly due to the fact that the biological and environmental pathways of nano-
materials are still largely unexplored (CCA 2008). Some efforts have been made to 
assess occupational-, consumer- and environmental exposure, however, both in regard 
to assess the level of exposure and to assess the applicability of current exposure 
assessment methods and guidelines.   
 
5.3.1 Occupational exposure  
For workers the primary route of exposure is assumed to be through inhalation 
and/or dermal contact after the manufacturing process of a nanomaterial for instance 
when a reaction chamber is opened, a product is dried, during the handling of products 
after their manufacture. Exposure is less likely during the manufacturing process itself 
since most nanomanufacturing processes are performed in a closed reaction chamber.  
However, unexpected system failure such as rupture of a seal could happen (Biswas and 
Wu 2005, Franco et al. 2007, Fujitani et al. 2008). 
Occupational exposure to ultrafine particles has a long history but for the 
moment, it is unclear to what extent analogies can be drawn to nanomaterials. 
According to Biswas and Wu (2005), active operations in production will lead to high 
spikes of ultrafine particle number concentration. Once these operations stop, a gradual 
decay will be observed due to primarily coagulation, evaporation, dilution, and/or 
deposition. The effects of spatial and temporal changes are important as well in order to 
evaluate exposure accurately. Whereas the fraction of the total ultrafine particle number 
concentrations generally decreases, fine particle number concentrations increases with 
time and distance from the point of emission (Biswas and Wu, 2005).  
The information and data publicly available about current levels of worker 
exposure to nanomaterials is very limited. This includes valuable information such as 
what kinds of nanomaterials workers are exposed to, where and how, the concentrations 
by dose or by particles number they are exposed to and what kinds of protective 
measures are used or are available (ICON 2006).   
Maynard et al. (2004) performed one of the first exposure measurements of 
unprocessed airborne SWCNT at four facilities that were using either the HiPCO or 
laser ablation production methods. Measurements where taken to assess the propensity 
for aerosol particles to be released during agitation and to measure the size of particles 
released into the air while SWCNT material was removed from production vessels and 
handled prior to processing. Airborne concentrations of SWCNT were estimated to be 
then lower than 53 μg/m3 whereas glove deposits of SWCNT during handling were 
estimated at between 0.2 mg and 6 mg per hand (Maynard et al. 2004).  
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Han et al. (2008) reported observing MWCNTs in the range from 172.9 to 193.6 
MWCNTs/cm3 in a MWCNT research facility where the researchers handled unrefined 
materials. Gravimetric concentrations of total dust ranged from 0.21 to 0.43 mg/m3. 
After implementation of protective control measures such as enclosing and ventilating 
the furnace these decreased to 0.018-0.05 MWCNTs/ cm3. 
Using various measuring instruments simultaneously Bello et al. (2008) 
evaluated the potential exposure to MWCNTs during CVD growth in a university 
research lab, and during subsequent handling as the CNTs are removed from the furnace 
and detached from the growth substrate. In contrast to Maynard et al. (2004) and Han et 
al. (2008), Bello et al. found no increase in the total particle number concentration and 
any particle size range during furnace operations compared to background. Total 
particle number concentration was found to be between 4000-7000 particles/cm3 which 
is considered to be normal since ranges measured in the indoor environment commonly 
varies between 2000 and 10,000 particles/cm3. Bello et al. did not find evidence either 
of individual or bundles of CNTs in various air samples or in the personal filter.  
Fujitani et al. (2008) compared the particle size distributions and morphology of 
aggregated/agglomerated fullerenes at Frontier Carbon Corporation in Japan, during 
work and non-work periods as well as an agitation process, and compared it to nearby 
outdoor air. They found that the particle number concentration of particles with a 
diameter <50 nm was not larger during the removal of fullerenes from a storage tank for 
bagging and/or weighing than in the non-work period. However, the concentration of 
particles with a diameter >1000 nm was observed to be larger during the non-work 
period. Similar to Maynard et al. (2004), Fujitani et al. (2008) found that the use of a 
vacuum cleaner reversed these observations.  
A significant concern is related to the processing including drilling and cutting 
of nanomaterial hybrid composites. Bello et al. (2008) investigated the airborne 
exposures generated in a research lab during the dry and wet cutting of composites 
consisting of advanced fibers and polymer matrix with and without CNTs. No 
significantly difference was observed compared to background during wet cutting, 
which is the usual procedure for such composites. Compared to background particle 
levels, dry cutting did, however, generate statistically significant quantities of nanoscale 
and fine particles regardless of the composite type i.e. CNT-carbon, CNT-alumina, and 
their respective base composites (Bello et al. 2008). 
Current worker exposure monitoring and assessments are hampered by the lack 
of one sampling method that can be used to characterize exposure (NIOSH 2006, 
Maynard and Aitken 2007). Some methods monitor and measure nanoparticles using 
mass concentration monitoring. This is, however, insufficient because of the low mass 
of nanoparticles. There exist relatively few methods for measuring the surface area of 
nanoparticles in real-time in the workplace, and each of them has limitations when it 
comes to measuring the surface area of particles above 100 nm (NIOSH, 2006). Other 
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methods are based on real-time measurement of nanometer aerosol concentrations, 
however, many of these have limited sensitivity to detect small particles and cannot 
distingue between engineered nanomaterials and other solid particles. Concurrent 
particle sampling by filter and particle characterization is needed, but this again would 
rely on statics and area sampling methods and hence only lead to estimates of the level 
of worker exposure (NIOSH 2006, Fujitani et al. 2008).  
 
5.3.2 Consumer exposure 
The number of products available to the consumer entailing nanomaterials or 
based on nanotechnology has increased rapidly within the last couple of years. The 
nature of the products is diverse and so is the nature of consumer exposure.  
In a first attempt, Hansen et al. (2008b) used the Technical Guidance Document 
for exposure assessment of nanoparticles in a number of consumer products. These 
products represent a facial lotion, a sunscreen lotion, a fluid product for outdoor surface 
treatment, and a spray product for indoor surface treatment. The calculations done by 
Hansen et al. (2008b) were based on default values and equations taken from Part 1, 
Appendix II – “Consumer Exposure”, in the TGD (European Commission JRC 2003a). 
In cases where the TGD did not contain any data, the default values were based partly 
on information from knowledgeable stakeholders and partly on estimated values. Very 
few producers/distributors provide information about the content of the nanomaterials in 
the products. However, using the best estimates available and/or worst-case 
assumptions, Hansen et al. (2008b) estimate consumer exposure to be 26, 15, and 44 
μg/kg bw/year for a facial lotion, a fluid product, and a spray product containing 
nanoparticles, respectively. From a survey on the industrial production and application 
of nanotechnology in the Danish industry, it is known that producers of sun lotions use 
10-20 nm TiO2 particles with a specific surface area of 50-200 m2/g as UV absorber and 
that the nanoparticles are present in concentrations up to 10% (Tønning and Poulsen 
2007). The route of exposure for a sun lotion will mainly be dermal contact. Intake of 
smaller quantities by contact with the area around the mouth is not taken into 
consideration. As the product is a “leave on” product, which should neither be diluted 
when used nor washed off, the quantity of active substance on the skin (Ader) for an 
adult can be estimated to be Ader= 800 mg for a sun lotion containing 10% of 
nanomaterial. Assuming that all nanoparticles penetrate the skin the potential uptake per 
kilogram body weight per day (Uder, pot) can be estimated. Uder, pot is equal to 40 mg/kg 
bw/day nano-TiO2 for women if the sun lotion contains 10% nanoparticles. For men 
Uder, pot is equal to 34 mg/kg bw/day. The conversion of the value of applied sun lotion 
in an adult compared to a child can be calculated using Equation 3 in Table 1 of Hansen 
et al. (2008b). The quantity of the active substance on the skin per application for a 2 
year old child is found to be Ader = 260 mg for a particle concentration of 10%. This 
value is about 3 times less than for an adult. Uder, pot would, on the other hand, be 2 times 
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higher i.e. 63 mg/kg bw/day. It should be noted that these uptake values are worst-case 
scenarios assuming full skin penetration of nanoparticles. In its latest opinion on the 
safety of nanomaterials in cosmetic products, the European Scientific Committee on 
Consumer Products stated that there is inadequate information on, among other issues, 
uptake via physiologically normal and compromised human skin (Scientific Committee 
on Consumer Products 2007). The extent to which nanoparticles actually penetrate the 
skin is currently a matter of considerable debate internationally and will probably 
depend on specific particle properties and the local environment in which they are used. 
The assessment of the overall consumer exposure has been hampered by both 
lack of information and lack of access to information about which and how many 
products are commercially available that contain nanomaterials or are based on 
nanotechnology, the content of nanosized materials for most products and consumption 
rates of nanoproducts and consumer behavior. Hansen et al. (2008b) propose a 
framework to aid exposure assessment in consumer products. The framework is based 
on categorizing consumer products according to location of the nanomaterial and 
grouping products into three different exposure categories: 
1. expected to cause exposure 
2. may cause exposure  
3. no expected exposure to the consumer 
 
Products that would typically fall under the first category are products with 
‘‘nanoparticles suspended in liquids’’ or ‘‘airborne nanoparticles” whereas products 
with ‘‘surface-bound nanoparticles’’ and ‘‘nanoparticles suspended in solids’’ would 
fall into the second and third category, respectively. 
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Figure 9: Distribution of the products with no, possible and 
expected exposure within each of the various product categories 
depending on the location of the nanomaterial in the product 
(Hansen et al. 2008c) 
 
Using the data behind figure 7 on the distribution of products into various 
categories of nanomaterials in combination with the exposure grouping illustrated in 
figure 9, it is found that expected consumer exposure is highest for products in the 
products categories “Appliances” and “Health and Fitness” (see figure 10). Expected 
exposure is 36% for products that fall into the category of home and garden whereas it 
is 58% for cross-cutting products. For the other categories of products, the expected 
exposure ranges between these two percentages except for appliances for which 
exposure is only expected for 17% of the products. Possible exposure percentages are 
equally high ranging between 20-30% except for food and beverages, and electronics 
and computers for which about 10% fall into the category of possible exposure.  
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Figure 10: Distribution of the products with no-, possible- and 
likely exposure within each of the various products categories 
(Hansen et al. 2008b). 
 
The exposure grouping is based on the physical state in the application phase 
when the consumer exposure is expected to be highest. It should be noted that some 
consumer products will change their exposure potential during the product life-cycle, 
e.g. for paints where nanoparticles will be in liquid form when the paint is applied but in 
solid form once the paint has dried. In this case the major consumer exposure is 
expected to be from the liquid paint, but weathering and physical abrasion of the dried 
surface could potentially lead to an exposure.  
A comparison of the exposure grouping with the materials used (see figure 4 and 
10, and Table 1 in Hansen et al. 2008b) shows that the expected and possible exposure 
is highest for Ag, TiO2, and ZnO (see figure 11). It is also interesting to note that the 
category of unclassified products, for which we do not have information on the material 
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used, is the one containing the highest number of products for which consumer exposure 
is expected. This lack of information about which kinds of nanomaterials are used must 
raise concerns not only because of the potential exposures but also about the potential 
hazards of these products to the consumer.  
 
 
 
Figure 11: A comparison between the exposure categorization and the nanomaterials used (Hansen et al. 
2008b) 
 
5.3.3 Environmental exposure 
Exposure of nanomaterials to the environment seems inevitable with the 
increasing production volumes and the increasing number of commercially available 
products containing nanomaterials or based on nanotechnology.  
Environmental routes of exposure are multiple and can stem from:  
 operations related to the production of nanomaterials such as cleaning of 
production chambers;  
 spills from production, transport, and disposal of nanomaterials or 
products; 
 the use and disposal of products containing nanoparticles including 
incomplete waste incineration and landfills; 
 wastewater overflow and ineffective sewage treatment plants (STP) 
unable to hold nanoparticles back or degrade them;  
 degradation of products containing nanomaterials (Biswas and Wu 2005, 
RS & RAE 2004, Boxall et al. 2008). 
The total load to the environment from current uses of nanomaterials is unclear 
and analytical methods to detect and quantify environmental concentrations of 
nanoparticles have yet to become available (Muller and Nowack 2008, Luoma 2008). 
However various estimates have been made both for individual products, nanomaterials 
and applications as well as product types. 
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Envirox 
Recently, Park et al. (2008) completed a hazard and risk assessment of a 
nanoparticluate cerium oxide-based diesel fuel additive known as Envirox. Envirox is 
diluted with diesel to extend and improve fuel burn yielding a final concentration of 
CeO2 in the diesel fuel of 5 mg/L. Park et al. (2008) estimated the ambient level of 
cerium by the use of modeling studies and drawing on historical data on atmospheric 
monitoring before and after Envirox was introduced into the diesel fuel used in buses in 
London and Newcastle in 2003 and 2005, respectively. A significant fourfold increase 
from 0.145 ± 0.064 to 0.612 ± 0.287 ng/m3 was observed in the cerium concentrations 
in the ambient air in Newcastle following the introduction of Envirox whereas no 
increase was observed in the samples taken from London. The lack of increase observed 
in London might be reflected in the low percentage of buses using Envirox passing the 
sites in London where the samples were taken  
Using various models, Park et al. (2008) also calculated the cerium emissions to 
the atmosphere for all EU Member States up to year 2020 for a baseline- and a diesel 
particulate trap application scenario under various best- and worst-case conditions – 
assuming a 5 ppm concentration of cerium oxide in the diesel fuel and that newly 
registered passenger cars, light- and heavy duty vehicles will be equipped with a filter 
operated on Envirox.  
Park et al. (2008) found that using traps to retain cerium emissions in 
conjunction with Envirox would reduce car emissions by more than 70%, buses by 
85%, and heavy trucks by almost 90% by 2020 taking 1990 as a baseline. The 
introduction of traps will reduce particular matter by more than 70,000 tons per year 
whereas 75 tons of cerium would be emitted to the atmosphere. In the worst-case, 
assuming that all diesel fuel is doped with cerium and fully emitted to the atmosphere < 
1255 tons would be emitted. 
The urban population of the EU will be exposed to about 0.2 g cerium oxide per 
year, whereas the rural areas and the average emissions along the highways would be 
about 6.6 g and 0.3 kg cerium oxide per square kilometer per year.  
Ignoring that traps might capture much of the particulate emission, Boxall et al. 
(2008) also estimated the emission of cerium oxide in vehicle exhausts. Assuming that 
using cerium oxide as an additive in all diesel fuel at 10 ppm would lead to an emission 
rate of 10 ppm from diesel fuel vehicles, Boxall et al. found an emission of 0.0010 g/km 
for the passage of 1000 vehicles.  The concentration at 50 m from the road would be 
0.0002 μg/m3, whereas it would be three fold higher at 5 m. The annual emission of 
cerium oxide from all vehicles in the UK was estimated to be 161 kg based on the 
estimated vehicle emission rates and the total annual mileage for vehicles.  
Park et al. (2008) also modeled the possible soil contamination along a typical 
highway assuming that all cerium oxide emissions would accumulate over a 40-year 
period and they found that estimated concentrations vary between 0.28 and 1.12 g/g, 
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depending on the soil depth at a distance from the edge of the highway. In comparison 
Boxall et al. (2008) estimated concentration in soil to be < 0.01 g/kg 
 
Nanosilver 
Luoma (2008) estimated mass release of silver from silver socks, silver wash 
machines and swimming pools assuming that 10 and 30% of the population in the U.S. 
use silver, that households that are wealthy enough will buy silver wash machines and 
that 1 million pools use silver as a biocide. Silver discharges from silver socks in the 
two scenarios were estimated to be in the range of 6-930 kg and 180-2790 kg 
respectively depending on the silver contents in the socks, whereas the contribution 
from silver wash machines was found to be 2850 kg. The contribution from the 
swimming pools was by far the largest found; it was estimated to be 30 tons. In another 
scenario, Luoma estimated the total future discharges to be 457 tons assuming that there 
will 100, 10, and 5 products in the future that resemble the silver discharged from the 
socks, wash machines and the swimming pools, respectively. After waste treatment this 
could be reduced to 128 tons provided that 80% of the discharges are treated sufficiently 
to remove 90% of the silver.  
 Blaser et al. (2008) estimated the silver emission into wastewater by multiplying 
the amount of silver in biocidal plastics and textiles with the release rate of silver ions 
from these products and the period the products are in contact with water. Assuming 
that the removal in the STP was assumed to range between 99-85% wastewater removal 
Blaser et al. (2008) found that the predicted environmental concentration (PEC) for the 
STP would be 18 μg/L whereas PECwater and PECsediment would be 320 ng/L and 14 
mg/kg, respectively.  
 
Cosmetics and personal care products 
Based on available information about the applied concentration of nanoparticles 
in cosmetics, personal care products and paints, Boxall et al. (2008) used a long series 
of algorithms (for among other pesticides, medicinal products, and ultrafine particles) to 
estimate the predicted environmental concentrations of nanoparticles in soil and water. 
Although anticipating that 10% market penetration probably provides a conservative 
estimate (with the exception of sunscreens), Boxall et al. calculated the PEC for three 
scenarios assuming that 10%, 50% and 100% of the products on the market contained 
nanoparticles. The highest total predicted concentrations in water was found to be for 
latex nanoparticles (103-1025 μg/L) stemming from laundry detergents followed by 
zinc oxide (76.0-760 μg/L) and titanium oxide (24.5-245 μg/L) used in among others 
paints and sunscreens. The use of hydroxyapatite in toothpaste and fullerene in 
cosmetics is estimated to lead to a environmental concentration of between 10.1-101 
and 0.31-3.13 μg/L, respectively. Predicted concentrations in soil range from 4.3-43 
mg/kg for nanolatex to <0.01 for CeO2.  
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Mueller and Nowack (2008) modeled the predicted environmental concentration 
for nano-Ag, nano-TiO2 and CNTs for air, water and soil in Switzerland. The 
calculations by Mueller and Nowack (2008) were based on a quantitative substance 
flow analysis of how nanoparticles from various products categories such as textiles, 
cosmetics, coatings, plastics, sports gear, electronics, etc. enter the environment through 
abrasion, outlet from the sewage treatment plants and/or waste incineration plants and 
landfills. Given the lack of information, numerous assumptions and estimates had to be 
made about worldwide production volumes, concentration of the nanoparticles in the 
products, levels of incombustible nanoparticles and behavior during wastewater 
treatment. For CNT, for example, it is estimated to be realistic that the worldwide 
production in 2007/2008 is 350 tons and that these are evenly incorporated into plastics 
and electronics. For the CNT that end up in the waste incinerator, it is furthermore 
assumed that 50% will be burned, 25% will end in the slag and 25% will become 
airborne. Of the 25% that become airborne, 99.9% will be caught in the filters of the 
waste incineration plant leaving 0.1% to enter the atmosphere. In a high exposure 
scenario, Mueller and Nowack (2008) assumed a worldwide production of 500 tons 
annually and that only 25% are burned and that only 99% of the airborne CNT are 
caught by the filters of the incineration plant.  
Boxall et al. (2008) estimated PECs for nanoparticles in cosmetics and personal 
care products whereas the scope of the analysis of Muller and Nowacks include among 
others textiles, metal products and cosmetics. Still Muller and Nowack found PECs that 
were lower – although in the same order of magnitude – as Boxall et al. (2008) for Ag 
in water and soil, and for TiO2 in air. This was the case even for the high exposure 
scenario, whereas estimates differ substantially for TiO2 in soil with several orders of 
magnitude. Some of the difference between the PECs could be related to the fact that 
Boxall et al. (2008) assumed that no nanoparticles would be retained in the sewage 
treatment plants, whereas Mueller and Nowack (2008) assumed that 97% and 90% of 
the nanoparticles would be cleared in the realistic and the high exposure scenario, 
respectively.   
 
5.4 Risk Characterization 
Risk characterization is defined as “estimation of the incidence and severity of 
the adverse effects likely to occur in a human population or environmental compartment 
due to actual or predicted exposure to a substance, and may include “risk estimation”, 
i.e. the quantification of that likelihood.” (European Commission JRC 2003a).  
Risk characterization is the final part of risk assessment where all the information 
gathered during the first three steps of risk assessment come together (CCA 2008). 
Often risk characterization boils down to the estimation of a risk quotient defined as 
PEC/PNEC. If the risk quotient is < 1 no further testing or risk reduction measures are 
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needed according to the European Commission JRC (2003b). If it is > 1, further testing 
can be initiated to lower the PEC/PNEC ratio. If that is not possible risk reduction could 
be implemented.  
Recently, a number of studies reported having completed risk assessments of the 
use of CeO2-based diesel fuel additive in the UK (Park et al. 2008), and the use of nano-
Ag, nano-TiO2 and CNTs in Switzerland (Mueller and Nowack 2008). Park et al. 
assessed the risk of CeO2 causing pulmonary inflammation. First, they estimated an 
internal dose of 3.8 × 10-7 cm2/cm2 by converting the retained dose into surface area 
units and then dividing by the area of the proximal alveolar region of the lung. Then 
they compared this value to the highest no-observed-effect level (NOEL) found in a 
number of in vitro toxicity studies. This value was 26.75 cm2/cm2. Assuming that in 
vitro exposure data can be accurately projected to the in vivo situation, Park et al. 
(2008) concluded that “it  is highly unlikely that exposure to cerium oxide at the 
environmental levels (from both monitored and modeled experimental data) would elicit 
pulmonary inflammation”. 
Mueller and Nowack (2008) reported having completed the first quantitative risk 
assessment of nanoparticles in environment. In a first attempt to derive PEC values, 
Mueller and Nowack used threshold concentrations of 20 mg/L and 40 mg/L reported in 
the literature for nano-Ag on B. subtilis and E. coli and considered it to be equivalent to 
a NOEC. For nano-TiO2 and CNT the lowest value found in the literature was <1 mg/L 
for algae, daphnia and fish (Mueller and Nowack 2008). Applying assessment factor of 
1000, the Predicted No Effect Concentration (PNEC) in water was found to be 0.04, 
<0.001 and <0.0001 mg/L.for nano-Ag, nano-TiO2 and CNT, respectively. Combining 
these PNEC-values with the predicted exposure, Mueller and Nowack (2008) calculated 
the environmental concentrations in Switzerland for nano-Ag, nano-TiO2 and CNTs 
stemming from textiles, cosmetics, coatings, plastics, sports gear, electronics, etc. 
Assuming worse-case exposure levels, Mueller and Nowack (2008) find that the risk 
quotient for nano-Ag and CNT is less than a one thousandth, and they state that their 
modeling suggests that currently little or no risk is to be expected from nano-Ag and 
CNT to organisms in water and air. Nano-TiO2, on the other hand, might pose a risk to 
organism in water – according to Mueller and Nowack (2008) – with risk quotients 
ranging from > 0.7 and > 16. PNEC for soil could not be determined due to lack of 
information.   
Risk characterization involves critically reflection of the data behind each step 
and determining what the overall risk will be (CCA 2008).  
In section 5.1-5.3 the current state of knowledge and most significant findings 
within each of the first three steps of risk assessment were presented, analyzed and 
discussed. Considering the results of this analysis along with the work done by Park et 
al. (2008), and Muller and Nowack (2008), it becomes clear that each element of risk 
assessment hold general as well as specific limitations and challenges. Risk 
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characterization being at the end of the line, the sum or maybe even the power all of 
these limitations are conveyed to calculating risk quotients for nanoparticles. 
Toxicity has been reported on for multiple nanoparticles as demonstrated in 
section 5.1, but for most nanoparticles these need further confirmation before one can 
say that a hazard has been identified. Multiple studies relevant for hazard identification 
have been carried out on C60, CNTs, quantum dots and nanomaterials, however, many 
of these studies are not meant to facilitate risk assessment in the sense that they use non-
standardized tests, have no coherent endpoint, and differ substantially with regard to 
species tested, methods of administration, dose range, way of particle preparation, 
duration of exposure, and effects observed and reported. This hampers identification of 
hazard univocally for most nanoparticles. Preliminary results furthermore indicate that 
the diversity of nanomaterials and their properties makes it an overwhelming challenge 
to conduct in vitro and in vivo evaluation of their biological effects (CCA 2008, RCEP 
2008). It is evident that the information provided is ‘all over the map’ making it 
impossible to systematically analyze the studies for properties of the nanoparticles 
which are important for the observed effects (Hansen et al. 2007, Warheit 2008).  
Dose-response estimates assumes a no effect threshold can be established and 
although some studies have reported observing a dose-response relationship there is no 
evidence of a dose threshold below which nanoparticle instillation ceased to cause, for 
instance, inflammation (Wittmaack 2007, Hansen et al. 2007). A dose-response 
assessment is furthermore hindered by the fact that it is unclear what the best descriptors 
for dose is and which properties determine or influence the inherent hazards of 
nanoparticles. The current lack of characterization of the nanoparticles tested in various 
studies makes it impossible to identify causality between observed hazards and specific 
physical and chemical properties. There is furthermore substantial limitation in our 
ability to determine individual and multiple particle characteristics simultaneously and 
in a consistent manner – both prior and during tests – when using different 
characterization techniques and/or across laboratories (RCEP 2008).  
Exposure assessment is hampered by difficulties in monitoring nanomaterial 
exposure in the workplace and the environment, and by the fact that the biological and 
environmental pathways of nanomaterials are still largely unexplored (CCA 2008, 
RCEP 2008). The assessment of  worker exposure is hampered by both technical 
difficulties such as the lack of one consistent sampling method that can be used to 
characterize exposure in real-time (NIOSH 2006) and by lack of information and data, 
for example, about how many workers are potentially exposed, what kinds of 
nanomaterials workers are or might be exposed to, where and how they are exposed and 
at which concentrations, by dose or by particles number, and what kinds of protective 
measures there are used or available (ICON 2006). As with worker exposure, analytical 
methods to detect and quantify concentrations of nanoparticles in the environment have 
yet to become available (Muller and Nowack 2008, Luoma 2008). The total load to the 
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environment from current of nanomaterials is unclear. Several studies have tried to 
assess current and future consumer and environmental exposure for individual products, 
nanomaterials, and applications as well as product types. As elaborated on in section 5.3 
many of these have been able to apply fairly simple mathematical equations and/or 
information available in the Technical Guidance Document to estimate the current and 
future exposure. However, in order to assess the consumer and environmental exposure 
to nanoparticles numerous assumptions had to be made about for instance: worldwide 
production volumes of nanoparticles, number of products produced entailing 
nanoparticles and at what concentrations, current and future market penetration, release 
from products throughout the life-cycle of the products by mass or other relevant 
metric(s), to what extend products become incinerated, end up in landfills or the sewage 
treatment plants, or end up directly in the environment, and release from waste 
incinerators and removal efficacy in the STPs, and their fate and distribution in surface 
water, soil and the air. These studies, no doubt, hold great value in regard to assessing 
the applicability of exposure assessment and should be seen as “proof of principle” 
rather than actual assessment of the exposure. Paucity of knowledge and lack of access 
to information hampers realistic exposure assessments.  
Recently the European Commission’s Scientific Committee on Emerging and 
Newly-Identified Health Risks (SCENIHR) delivered their opinion on the 
appropriateness of the risk assessment methodology in accordance with TGD for 
assessing the risks of nanomaterials. SCENIHR (2007) note that the TGD make “very 
little reference to substances in particulate form”. Although SCENIHR concluded that 
the TGD are “generally likely” to be able to identify the hazards associated with the use 
of nanoparticles, they found that the methodologies needed improvements on a number 
of areas, such as: 1) mass concentration might not be the most significant metrics in 
determination of exposure, 2) state of agglomerations of nanoparticles depends on the 
environment and affects their properties, and 3) biological processes involving 
nanoparticles are still largely unknown. Although SCENIHR note that these 
improvements are needed, they give no recommendations on how these improvements 
should be made in practice. 
With respect to environmental exposure the SCENIHR expert panel is not even 
able to make a clear assessment of the validity and appropriateness of existing 
methodologies. They state that “In the absence of sufficient data on the fate and effect of 
nanoparticles on the environment, it is neither feasible nor appropriate to propose firm 
rules on how substances in nanoparticle form should be evaluated. Instead the 
applicability of existing methods for risk assessment of nanoparticles should be 
evaluated”. As noted by SCENIHR chemical risk assessment is a very complex process 
and the determination of risks associated with nanomaterials is an even more complex 
process than with conventional bulk materials (SCENIHR 2007). It is important to 
emphasize that the current uncertainties related to the risk assessment of nanoparticles 
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are “…not simply uncertainties in the values of some traditional parameters, but rather 
the uncertainties about the potentially unique or significantly modified causal 
mechanisms themselves” (SCENIHR 2007).  
In order to apply uniform procedures for risk assessment of nanomaterials, calls 
for standards applicable to nanomaterials are frequently made. At present, there exist no 
standard procedures or widely accepted methods for assessing nanomaterials’ safety 
hazards (Environmental Defense and DuPont 2007). When looking at the individual 
steps in the risk assessment procedure, it becomes apparent that even at the starting 
point – hazard identification – there is no internationally agreed upon best practices. For 
example, the selection of a set of hazard relevant physico-chemical parameters is being 
discussed in the scientific community (SCENIHR 2006, Oberdörster et al. 2005a, b), 
and no standardized toxicity test guidelines exist. For exposure assessments, there are 
no standards for how to measure nanoparticle exposure in the body, the workplace 
(NIOSH 2006) and the environment (SCENIHR 2007), and effects assessments are 
hampered by the lack of basic toxicological test methods.  
Although standardization work in the field of risk assessment of nanomaterials is 
currently underway on an international scale (OECD 2007), it is important to remember 
that standardization of chemical risk assessment procedures (including toxicity tests and 
related exposure/effect assessment protocols) were underway for more than twenty 
years. Much of this development was not just concerned with technical improvements 
of tests, but was closely connected to the development of environmental regulation to 
provide stakeholders with useful legitimate instruments rather than the scientific 
communities’ interest in the subject (Halffman 1998). Hopefully, we have learned from 
these past experiences, but a certain lag must be anticipated due to the deficits in 
scientific studies and procedures in the emerging field of nanotoxicology.  
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6. Discussion 
The aim of this PhD thesis was threefold:  
1. to investigate whether existing regulation is adequate in the short and the long 
term;  
2. explore the feasibility of risk assessment for the purpose of dealing with the 
complex emerging risks of nanomaterials, and finally;  
3. provide recommendations on how to govern nanotechnologies protecting human 
health and the environment.  
In the following, the limitations of current regulation of nanomaterials and 
applications will be discussed and recommendations will be provided on how to address 
these limitations in the short term. The analysis of the applicability of the current 
regulation on nanomaterials showed that (eco)toxicological data and risk assessments 
are often necessary to support current regulation. However, risk assessment holds a 
number of limitations as well, and the short and long term feasibility of risk assessment 
of nanomaterials is discussed. Potential alternatives will be addressed shortly. Some of 
them have already been applied on nanomaterials.  
 
 
6.1 Identified limitations of current regulation of nanomaterials 
  
The analysis of the existing regulation showed that there are a number of 
potential gaps and each of them will be dependent on the specific nanomaterial and its 
specific application (Franco et al. 2007).  
Though there is no specific mentioning of nanomaterials in any of the EU 
legislation, in general it seems as if nanomaterials are covered by the broad scope of the 
various pieces of legislation. The question is whether nanomaterials are covered when it 
comes to the specifics. For REACH the main areas of concern seem to be that it is 
unclear when a nano-equivalent of a bulk substance should be registered under REACH, 
and that production thresholds for when (eco)toxicological information has to be 
submitted, are not currently met for many nanomaterials (although they might be in the 
near future). Furthermore, even though companies are urged to use already existing 
guidelines, both the European Commission (CEC 2008a) and its Scientific Committee 
on Emerging and Newly-Identified Health Risks (SCENIHR 2007) as well as others 
have pointed out that current test guidelines supporting REACH are based on 
conventional methodologies for assessing chemical risks and may not be appropriate for 
the assessment of risks associated with nanomaterials. Somewhat similar issues have 
been raised for pharmaceuticals where the concern is that current product standards may 
not be suitably designed to address various aspects relating to novel applications of 
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nanotechnology in nanomedicine.  Furthermore, if the estimated environmental 
concentration of medical products is below 0.01 ppb and “no other environmental 
concerns are apparent”, no further actions are to be taken for the medical product in 
terms of environmental risk assessment. Such pre-defined action limit could potentially 
be problematic since the new properties of nano-based products are expected to also 
affect their environmental profiles.  
Chaundry et al. (2006) observed that potential gaps of regulation of 
nanomaterials seem to fall into two main categories. For one category, the key piece of 
regulation relating to a sector, application, product or substance fails to address an 
aspect of particular interest – for instance, if a piece of legislation is intended to address 
the human health impacts but fails to address possible environmental impacts of 
nanomaterials or nanoproducts. For the second category, a piece of legislation is 
intended to address a specific aspect of particular interest to a sector, application, 
product or substance but fails to address it due to exemptions (e.g. threshold, volume or 
tonnage related), lack of foresight, limitations in technical or scientific knowledge, etc. 
(Chaundry et al. 2006). 
The identified gaps in this analysis fall into two, however somewhat different, 
categories. The first category concerns whether nanomaterials are covered by current 
legislation when it comes to 1) definitions of a substance, novel foods, hazardous waste, 
etc. and 2) thresholds values not tailored to the nanoscale, but based on bulk material, 
see e.g. REACH. The second category relates to the lack of metrological tools and 
toxicological data and the fact that occupational and environmental exposure limits 
cannot be established with existing methodologies – as required by some pieces of 
legislation e.g. pharmaceuticals regulation and the Safety at Workplace Directives.    
 
 
6.2 Recommendations in regard to the “Incremental approach”  
 
The Commission of the European Communities has adopted a so called 
incremental approach which focuses on adapting existing laws to regulate 
nanotechnologies and amending them in order to deal with nanomaterials. So far, the 
Commission has only found it appropriate to implement one amendment, i.e. carbon 
losing its exemption status under REACH. However, the other limitations need to be 
addressed as well sooner rather than later for the incremental approach to be successful, 
especially in view of the current pace of development of nanomaterials and applications. 
In order to deal with the limitations of the Safety at Workplace Directives, it is 
recommended that occupational exposure of nanoparticles is limited as much as 
possible, while international standards for the safe handling of nanoparticles in 
laboratories and other workplaces is developed. Currently, a great deal of international 
attention is given to the identification of potential exposure scenarios at workplaces, 
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establishment of standard guidelines for workplaces and laboratories, identification of 
protection measures and development of efficient metrology infrastructures (NIOSH, 
2006). For instance, the EU has funded a number of projects, such as ParticleRisk, 
NanoSAFE 1 and 2, with the main purpose of developing methods for detecting, 
tracking, and characterizing nanoparticles along with risk assessment and management 
procedures to secure industrial production of nanoparticles. Another project, 
NanoDERM, studies the quality of human skin as a barrier against nanoparticles, which 
is highly relevant and timely for both workers and consumers (European Commission 
2007).  
Many environmental laws (e.g. REACH, Directives on hazardous waste, etc.) 
are based on (eco)toxicological classification of substances. Terms like ‘‘toxic’’ or 
‘‘persistent’’ are often used as triggering factors to establish specific regulations, set 
emission limits, prohibitions and other requirements. These rules acquire a consistent 
meaning only possible when (eco)toxicological data are available for a substance. 
Although work is underway in order to produce such (eco)toxicological data for 
nanoparticles, much of this work is only just getting started. For instance, the EU has 
funded a number of projects (e.g. IMPART-NanoTOX) attempting to increase the 
understanding of toxicological impact of nanoparticles on human and environmental 
health (European Commission 2007). A regulatory gap, on the other hand, emerges 
when there is insufficient scientific evidence or lack of reliable data. In this context 
REACH will play a crucial role because it should provide the necessary information to 
make consistent use of other laws. For this reason, it is recommended that all 
nanomaterials are treated as new substances under REACH until it is clarified whether 
all or only a few of them display unique (eco)toxicological properties at the nanoscale. 
Lowering the current 1 ton per annum threshold per producer or importer for engineered 
nanoparticles to different thresholds and units than mass is recommended (RS & RAE, 
2004, European Commission, Health and Consumer Protection Directorate General 
2004).  
Besides providing the traditional physicochemical properties when registering a 
substance, producers and importers of nanomaterials should be obliged to provide 
additional information such as shape, crystal structure, surface- area, charge and 
chemistry paying respect to the specific properties of nanomaterials. The new European 
Chemical Agency should develop and provide guidance to primary manufacturers and 
down-stream users on safety assessment of nanomaterials and a semi-governmental 
institution should be established in order to help industry do nanomaterials’ 
characterizations and to do (eco)toxicological testing.  
Waste management regulations require stricter protective measures for handling, 
treatment and final disposal of wastes according to their (eco)toxicological 
characteristics. Since there are reasons to suspect that nanoparticles can display 
hazardous properties when released into the environment, it is recommended 
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introducing ‘‘free nanoparticles’’ in Annex II of the Directive on hazardous waste, 
which lists the constituents of a waste that render it hazardous.  
Despite the many knowledge and regulatory gaps identified, one of the largest 
obstacles is the lack of access to key information along the life cycle of the products. 
Key information during production, extraction and refining, manufacturing, use and 
final disposal of the products is not available due to manufacturer’s secrecies and non-
disclosure policies. It is impossible to obtain information on specific production 
volumes, the number of product units, concentration of nano-materials/particles in final 
products, or mass flows of nanoparticles from the raw material to the final product. 
Furthermore quantitative and qualitative characterizations of by-products, such as 
fullerenic soot and carbon nanotube fibres, as well as their fate cannot be exhaustively 
described.  
Without such information, public authorities will have a hard time monitoring 
and evaluating the effectiveness of the incremental approach. Some claims of 
confidential business information seem unreasonable (Hansen and Rejeski, 2008), and 
providing wider access to at least some information seems to be an important step in 
facilitating the availability of information up-and-down the supply chain and to other 
interested parties. In the case of emerging technologies, including nanomaterials, at a 
minimum information made publicly available for regular substances under REACH 
should also be made available i.e.: name, classification and labeling, physicochemical 
data, including information on pathways and environmental fate, results of each 
toxicological and ecotoxicological study, any derived no-effect level or predicted no-
effect concentration, guidance on safe use, and, to the extend possible, analytical 
methods for detecting direct human exposures or discharge to the environment. 
 
 
6.3 Recommendations in regard to voluntary environmental programs  
 
As discussed in section 4 DEFRA has implemented a voluntary environmental 
program (VEP) in the UK so that industry can submit such information and help 
DEFRA “develop a better understanding of what types of engineered nanoscale 
materials are likely to be produced in the UK, and to build up an understanding of their 
properties and characteristics so that the potential hazard, exposure and risk associated 
with these materials may be determined.” (DEFRA 2006). However, so far, 
participation in the program has been limited and disappointing – perhaps due to the 
lack of incentives and obvious benefits for companies to participate.  
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In general these incentives and benefits can be categorized into two types: 
 The carrot approach, defined as providing positive incentives such as cost-
savings, technical assistance or other subsidies, and 
 The stick approach defined as providing negative incentives such as threatening 
a harsher outcome such as legislation, for example, if a voluntary agreement is 
not reached. 
Although DEFRA’s VEP is completely voluntary, they do not include elements 
of these two types of incentives (particularly “stick” elements), since there are neither 
cost savings, technical assistance nor other positive incentives, nor is there more than a 
weak current threat of legislation, for the moment. In past VEPs, it seems that the 
“threat of regulatory intervention” used in combination with unbiased technical- and 
non-technical information support, progress reports, and favorable publicity has been 
outstanding incentives for participants (Hansen and Tickner 2007). A number of ways 
to provide these incentives have not yet been explored in, not only DEFRA’s, but also 
other nanomaterial VEPs implemented around the world (Hansen and Tickner 2007). In 
the state of Massachusetts, for example, the 1989 Toxics Use Reduction Act includes 
mandatory materials accounting reporting for chemicals and bi-yearly pollution 
prevention planning. An industry fee on chemicals also funds both voluntary and 
confidential engineering technical assistance provided by the state government, as well 
as training, research and demonstration projects undertaken by the Toxics Use 
Reduction Institute at the University of Massachusetts Lowell. The training and 
technical support provide the “capacity” critical to innovation in safer materials and 
processes. This type of support is particularly important for small and medium sized 
firms that might pose the greatest risks where there is a general lack of expertise in 
health, safety, and environment. Non-technical support could be provided through the 
publishing of various newsletters, agency guidance documents on determining various 
nanomaterial characteristics, (eco)toxicological testing and monitoring, the 
establishment of a searchable nanomaterials database, the establishment of a website for 
participants to exchange information and firm-to-firm dialogues (Hansen and Tickner 
2007). Guidance on determination of characteristics of nanomaterials would also help 
ensure consistency and reliability, as would guidance on health and safety testing. This 
guidance should offer clues how to report various problems experienced while gathering 
information (NPPTAC 2005). Hearing about and learning from the problems that 
participants experience when trying to do characterizations of their unique 
nanomaterials and trying to apply present environmental, health, and safety testing 
methods, is probably one of the most valuable assets of any program – given the fact 
that our understanding of the properties of nanomaterials, their application, and what 
constitutes their hazards and exposure pathways is still in its infancy. Guidelines would 
also help ensure the quality of the information being submitted. To further ensure the 
quality of information, periodic reporting should be made and feedback should be 
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provided back and forth between sponsors and participants. This includes getting 
external feedback from independent scientists or specialists and other stakeholders. 
Having signed agreements, which include a commitment to assure safe manufacturing 
and safe products, provide participants with a more stable regulatory environment. This 
can be an incentive for them to develop plans for information gathering, and safety and 
health management of nanomaterials. And having participants write progress reports 
could help ensure transparency to the public and to the regulating authorities (Beardsley 
et al. 1997).  A key part of any effort to improve and ensure transparency is giving the 
public and other stakeholders access to information. Such assess needs to be provided in 
terms of both raw data (so that data can be reanalyzed) and in a publicly accessible 
format. Ideally, representatives of the public should be involved in the design of the 
reporting format and resources should be provided so that organizations representing the 
public interest are able to adequately and competently review submissions, reviews, and 
reports. This is critical for ensuring the accountability of any program. A key element in 
ensuring participation in the VEP and increased likelihood of success is favorable 
publicity for participants. As already mentioned, this can be provided in a number of 
ways such as posting awards, giving press releases, etc. Additionally to such positive 
incentives, there should also be a number of disincentives for not participating in a VEP 
for nanomaterials. Disincentives could include the creation of a list of companies not 
participating in the VEPs on nanomaterials, but known to the DEFRA to develop and 
manufacture nanomaterials. The U.S. EPA has such a list of producers last known to 
produce orphan chemicals in their High Production Volume challenge program (OPPT 
1999). Another disincentive could be informing non-participating firms  every time one 
of its competitors decides to participate – an approach that was used effectively in the 
Energy Star Office Products program in the USA (Beardsley et al. 1997).   
Disincentives for disclosure information such as potential future liability and 
supply chain dynamics are relevant with regard to nanomaterials. The question is what 
can be done to eliminate such disincentives? Davies (2006) suggested that the two be 
combined in the case of nanomaterials so that the insurance industry would refuse to 
insure any nanomanufacturer who did not adopt some oversight framework such as the 
one recently proposed by Environmental Defense and DuPont (2007), which urges 
companies to share not only information, but also insight into the basis of risk 
assessment and management decisions with other companies within the supply chain, 
including those involved in managing waste from the manufacture, use, or disposal of 
the material or product. 
Implementation of these recommendations will only address some of the 
immediate concerns related to the application of the incremental approach to regulate 
current manufacturing and use of nanomaterials. However, they fail to address other 
concerns, especially the ones related to nanomaterial yet to be developed, i.e. the third 
and fourth generation of nanotechnological development.  
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Past experience with VEPs suggests that some kind of mandatory regulatory 
framework will be needed somewhere down the road, since participation to a 
considerable extent depends on the existence of a regulatory framework that would 
impose penalties on firms that do not undertake proactive measures for self-regulation. 
Indeed, VEPs are likely to be less effective without the backstop of mandatory 
regulation (Khanna and Damon 1999). As such any VEP on nanomaterials should be 
made mandatory after no more than three years in order to create a “threat of regulatory 
intervention”. The three-year leap period would give early participants time to adjust 
and provide a period of “trial and error” and to get something going while a more 
permanent regulatory program is developed. Having the VEP become mandatory after 
three years would also eliminate the problem of “orphan” nanomaterials. It would also 
ensure that first-moving companies get early benefits; and that there is a level regulatory 
playing field within a reasonable period of time, as competition gets tougher. One could 
fear that both, regulators and firms, will not be too keen on having a VEP turned into a 
mandatory regulatory framework since they might want to avoid the complex and costly 
conflicts that often are associated with regulatory reform (Baggott 1986). According to 
Lyon (2003), however, the initial VEP may reduce political resistance to future 
regulatory mandates because participants have less incentive to oppose new legislation 
when they receive government support, such as technical assistance, to implement risk 
management practices. 
 
 
6.4 Limitations of risk assessment in regard to nanomaterials 
 
Since early discussions about nanotechnology related risks, risk assessment has 
been put forward as the number one approach (along with LCA to some extent 
(Klöpffer et al. 2007)) in regard to understand the risks associated with the application 
of one kind of nanomaterials, namely nanoparticles, in our society. An official in charge 
of regulatory aspects of nanotechnology at the European Commission has even been 
cited for arguing that there is no regulatory void on nanotechnology because EU rules 
impose a risk assessment on all products and that nanomaterials were no exception to 
this obligation (Brekelmans cited in EurActiv 2008). Hence, the importance of risk 
assessment in providing the backbone in relation to current and future regulation of 
nanomaterials should not be underestimated.  
What is worrying is that the present analysis of risk assessment identified a 
number of limitations and flaws in relation to each of the four elements of the risk 
assessment framework when applied on nanomaterials. It is currently impossible to 
systematically link reported nanoparticle properties to the observed effects for effective 
hazard identification. For dose-response assessment, it was unclear whether a no effect 
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threshold can be established and what the best hazard descriptor(s) of nanoparticles is 
and what the most relevant endpoints are.  
There is a serious lack of characterization of the nanoparticles tested, which 
makes it difficult to identify which key characteristics – or combinations of key 
characteristics – determine the hazards documented in (eco)toxicological studies of 
nanoparticles. The nine inherent properties identified as possible hazard descriptors by 
Hansen et al. (2007) and others may possibly be reduced as knowledge advances in the 
field of nanotoxicology, and it is likely that the toxicity of nanomaterials is determined 
by combinations of these properties (Hansen et al. 2007, Wittmaack 2007). But perhaps  
properties not yet identified in the scientific literature may be relevant for the hazard 
identification of nanomaterials. 
Although the lack of characterization is troublesome, it is hardly surprising as 
nanotoxicology is a very young field of research stemming from ultra fine particle 
research (Oberdörster et al. 2005a). A true understanding of the hazardous properties 
that materials begin to exhibit at the nanoscale requires a level of interdisciplinary 
research that has not yet been reached. In order to conduct and interpret scientific 
studies on the hazardous properties of nanomaterials, strong interdisciplinary 
collaboration is needed between nanoscientists, (eco)toxicologists and physicists, 
chemists, and material engineers.  
The analysis of the limitations of risk assessment furthermore showed that the 
third element of risk assessment – exposure assessment – is hampered by difficulties in 
monitoring nanomaterial exposure in the workplace and the environment, partly due to 
the fact that the biological and environmental pathways of nanomaterials are still largely 
unexplored (CCA 2008) and partly due to the paucity of knowledge and lack of access 
to information which hampers realistic exposure assessments. Risk characterization, 
being at the end of the line, the sum or maybe even the power of all these limitations are 
conveyed to calculating risk quotients for nanoparticles. Considerable work is still 
required if future risk assessment of current nanomaterials and products is to be relevant 
and reliable.   
Despite some moves to respond to the limitations of risk assessment and 
uncertainty rather than simply discuss them, coordinated action seems slow in 
emerging. In 2001, a report written by an expert panel commissioned by the European 
Environment Agency (EEA) on how to avoid repeating the mistakes of the 
technological development recommended looking out for “warning signs” such as 
materials exhibiting novelty, persistency, readily dispersed, bioaccumulative, and that 
lead to irreversible action (EEA 2001). These characteristics resonate with many 
nanomaterials (RCEP 2008), some of which have novel properties, are capable of being 
incorporated in highly diverse products, may be transported to places in new ways, and 
may be designed to be persistent. Too little is known to predict the environmental fate 
of nanomaterials and feasible documentation of environmental dispersion through 
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monitoring is not expected in the short term (RS & RAE 2004). The extent to which 
specific nanomaterials are bioaccumulative or lead to irreversible action is largely 
unknown, but the current state of knowledge suggests that the potential exists for such 
behavior under some circumstances (SCENIHR 2007). The global response to these 
warning signs has been patchy, at best. In general, government policy has been slow to 
respond, to gather essential data on production and to use patterns and personal 
protection equipment. Arguably, efforts have been better than those seen with many 
earlier technologies but they are still far from ideal. A number of reports make specific 
recommendations on developing responsive research strategies (Oberdörster et al. 
2005b, Maynard 2006, Moore 2006, Tsuji et al. 2006). Calls for proposals in the 
European seventh framework program reflect some of these recommendations, while 
countries like Australia are beginning to develop integrated environment, safety and 
health research programs. In the USA, the nanotechnology risk-research portfolio looks 
impressive on paper, although it only accounts for between 1 to 4% of the total NNI 
nanotechnology R&D budget (Maynard 2006). Research strategies that target 
recognized areas of uncertainty and address many of the issues raised previously, should 
be relatively easy to develop, as the critical questions to be addressed are generally 
agreed upon (National Nanotechnology Initiative 2008, Hansen et al. 2008a).  
Besides the dangers of missing important areas entirely, because the right 
questions have not yet been identified, there are a number of additional problems when 
it comes to risk assessment of future nanomaterials, their application and their variety – 
especially when we consider the pace of the technological development. 
 
6.4.1 Case-by-case risk assessment of nanoparticles 
The need to assess the risk of nanoparticles on a case-by-case basis is often 
mentioned in order to take the unique properties of nanomaterials into consideration 
(SCENIHR 2007, Environmental Defense and DuPont 2007) and an official in charge 
of regulatory aspects of nanotechnology at the European Commission has even been 
cited for stating that product authorization as well must be conducted “on a case-by-case 
basis” (Brekelmans cited in EurActiv 2008). 
While chemical risk assessment is based on the fact that the chemical identity 
governs the fate and effects of a chemical, the situation for nanomaterials may be 
somewhat different. By definition, the properties of nanomaterials cannot be determined 
by their chemical composition alone, and hazard identification of nanomaterials – and 
specifically nanoparticles – has come under intense scrutiny in recent years. However, 
we are still in what one could term the “pre-hazard identification”-phase, meaning that 
we do not know which characteristics determine the hazards of nanoparticles. As noted 
by Kulinowski, executive director of the Center for Biological & Environmental 
Nanotechnology at Rice University “We have to remember that so much of what needs 
to be done is still in the discovery stage” (Hanson 2008). There seems to be a general 
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agreement that the hazards will depend on surface area, surface charge, surface 
chemistry, state of agglomeration as well as chemical composition (Hansen et al. 2007), 
and especially surface area/reactivity has been mentioned as new “nano-relevant” 
properties for inclusion in hazard identification. However, for the time being, all of the 
mentioned particle characteristics may impact the overall hazard and since the causal 
relationships still need to be discovered, further research is needed in this area before 
relevant data demands for hazard identification purposes can be defined. Even with 
well-defined data demands, the experiences from chemical risk assessments tell us that 
case-by-case risk assessment of nanoparticles will be very time- and resource intensive. 
For nanomaterials, this situation is further complicated by the fact that the hazard 
characteristics will not only be linked to the chemical identity and that a large number 
of combinations of characteristics may influence the overall hazard. For instance, there 
are 20 different structural types of single-walled carbon nanotubes alone and their 
length can vary from 5 to 300 nm. According to Schmidt (2007) four different processes 
exist for manufacturing them, five methods for purifying them, and ten surface coatings 
are typically applied – hence there are up to 50,000 potential combinations of single-
walled carbon nanotubes – and each version may have different chemical, physical, and 
biological properties that determine their overall hazard. This example may serve to 
show the complexity and how demanding case-by-case evaluations are. However, not 
all of these single-walled nanotubes are expected to be of commercial relevance. On the 
other hand, there are numerous other kinds of nanoparticles such as fullerenes, quantum 
dots, metals and metaloxide nanoparticles.  
 
6.4.2 The pace of development 
While the completion of risk assessment of chemicals has been slow in the past, 
the pace of nanotechnological development and commercialization has not as illustrated 
in section 2. The number of products claiming the use of nanotechnology has doubled 
within the last two years (Project of Emerging Nanotechnologies 2007), and it is 
projected that 2 million workers will work in the nano-industry within 2014. In a recent 
commentary published in Nature Nanotechnology, a panel of experts listed the great 
challenges in the field of nanotoxicology over the next 15 years, ranging from the 
development of strategic research programs to the validated alternatives for in vivo 
nanomaterial toxicity tests (Maynard et al. 2006). They recommend that, for instance, 
strategic programs that enable relevant risk-focused research are developed within the 
next 12 months, models for predicting the potential impact of engineered nanomaterials 
on the environment and human health are developed within the next 10 years and 
methods to evaluate the toxicity of engineered nanomaterials are developed and 
validated within the next 5 – 15 years (Maynard et al. 2006). As the authors of the 
article note, meeting these challenges over the course of the next 15 years will depend 
on coordination, collaboration, resources and ingenuity, even if effort to meet these 
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challenges is assumed to be coordinated and fully funded. Even if the classical chemical 
risk assessment framework turns out to be adaptable for the assessment of the risks of 
nanoparticles, despite the limitations noted above, it is, however, important to remember 
that these simple “passive” nanoparticles only represent the “first-generation” of the 
nanotechnological development (Roco and Renn 2006). The second and third 
generation started in 2000 and 2005 whereas the fourth generation of nanotechnological 
development is expected to begin in the near future (i.e. 2010). This generation is 
projected to involve the development of heterogeneous molecular nanosystems where 
each molecule in the nanosystem has a specific structure and plays a different role 
(Roco and Renn 2006). 
If the recommendations by Maynard et al. (2006) are implemented, it means that 
we might be able to assess the human health and environmental risks of passive 
nanoparticles around 2020 – at the time when the development of nanotechology is 
about to end its four generation of development and enter a fifth according to Roco and 
Renn (2006).  
 
 
6.5 Alternatives to risk assessment  
 
It might be naïve to suggest that risk assessment should be abandoned due to the 
many and profound limitations identified and discussed here. It is, however, also naïve 
to suggest that risk assessment will be able to adequately inform decision makers on 
how to protect human health and the environment despite of these limitations any time 
soon.  
Several government agencies, academic scholars, industrial as well as NGOs 
have argued that the basic principles of risk assessment – hazard identification, dose-
response assessment, exposure assessment and risk characterization – can be applied 
effectively to nanoparticles as long as some adjustments are implemented (Nordan et al. 
2006, Environmental Defense and DuPont 2007, CCA 2008). In general, it could seem 
as if several stakeholders, on the one hand, first advocate in favor of using the 
traditional risk assessment approach after which they, on the other hand, point to a lot of 
fundamental challenges that need to be addressed before risk assessment can actually be 
applied effectively to nanoparticles (SCENIHR 2007, U.S. EPA 2007, EFSA 2008, 
CCA 2008).  
Given the limitations of risk assessment and given the future impact on every 
aspect of our lives and society that nanotechnology is expected to have, alternative 
decision making tools should be explored and new ways to govern and regulate 
nanomaterials should be sought.  
One tool that has already been applied on nanomaterials is MultiCriteria 
Decision Analysis (MCDA) (Linkov et al. 2007). The common purpose of MultiCriteria 
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Decision Analysis methods is to evaluate and choose among different decision 
alternatives based on multiple criteria, using systematic and structured analysis in 
contrast to “ad hoc” decisions. A number of different MCDA-methods exist following 
various optimization algorithms, varying in both the types of value information needed 
and in the extent they are dependent on computer software. Some techniques rank 
options whereas others identify a single optimal alternative and again others 
differentiate between acceptable and unacceptable alternatives. Key issues in relation to 
MCDA are:  
1) who defines what the initial criteria are;  
2) what alternatives are available to the decision maker; 
3) how the different criteria are translated into a numerical score in order to rank 
the different alternatives (Mayer and Stirling 1999).  
Other available tools yet to be applied to nanomaterials are Adaptive 
management and Bayesian decision making. Adaptive management is probably the 
decision making tool that is most often mentioned as a vital component of management 
of complex and uncertain risks (Holling et al. 1978, Holling 2001), however, it has yet 
to be applied on nanomaterials. Adaptive management sees the management of a risk as 
a process consisting of many small decisions rather than a “one hit” decision. In 
Adaptive management, the decision maker takes a decision which is then interpreted as 
a hypothesis that needs to be tested and validated. Monitoring is implemented to see 
whether the hypothesis is to be confirmed or rejected. If the hypothesis is rejected a new 
decision is made and the process starts all over again. Bayesian decision making might 
be another option. In short, Bayesian statistics uses the knowledge from past 
experiences to tell something about the probability for future scenarios. In Bayesian 
decision making, a decision is made on the basis on the evidence available at one point 
in time. As new and more  evidence becomes available, regulators and decision makers 
can find out how much they should adopt and maybe change their original decision in 
the light of the new evidence by using Bayesian decision making (Pascual, 2004). It is 
of vital importance that these methods are explored and utilized to the fullest and that 
their strengths and weaknesses are evaluated in the view of nanomaterials. 
In the face of uncertainty, a frequent response is calling for more research before 
action is taken. Yet it is important to remember that “Experts have often argued at an 
early stage that we ‘know enough’ to take protective action” (EEA 2001). Deciding 
when to act and when to refrain from taking action is often a difficult call. Good policy 
depends on identifying the right balance between information and action while keeping 
the end-point (preventing harm) in mind, and incorporating review procedures for 
course corrections. It is over 15 years since first indications of nanomaterial harm were 
published (Oberdörster et al. 1992), and in the intervening time, an increasing body of 
literature has been developed on how nanomaterials interact with people and the 
environment (Hansen et al. 2007). Yet many governments still call for more information 
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as a substitute for action, and there are indications that understanding and managing the 
risks of engineered nanomaterials is being paralyzed by analysis. It is clear that more 
scientific information is needed, but we need to act on what we know now to enable 
industry to produce market nanotechnology-enabled products that are as safe as 
possible. Engineered nanomaterials are already on the market and in some cases, the 
risks are poorly understood and ineffectively regulated. Applying current knowledge to 
nanotechnology oversight will not solve every problem, but it will help prevent basic 
mistakes being made while the knowledge needed for more effective oversight is 
developed (Hansen et al. 2008a). 
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7. Conclusion 
The development of nanotechnology has been rapid by almost any metric one 
can think of – governmental funding, industrial patents and number of research 
publications on nanotechnology in general and nanorisks in specific. Nanomaterials are 
currently used for various kinds of applications and the number of consumer products 
proclaimed to contain nanomaterials is increasing rapidly. Little is known, however, 
about how many products on the marked actually contain nanomaterials, how many 
units are produced and sold of a given product or how much nanomaterial is used in 
each of the individual products. Very little is furthermore known about the production 
volumes at which nanomaterials are currently produced and how these materials are 
applied in various industrial applications. Besides application with regard to food 
packaging, processing, etc., projected applications include: remediation of contaminated 
soil and groundwater, fuel cells and batteries, medical applications, drinking water 
treatment, and weapons and explosives. The current production and use of 
nanomaterials is most likely not representative for the future use and production, but 
factual information is hard to obtain which hampers regulation and risk assessment of 
nanomaterials in the short and the long term. 
At the moment, issuing a specific long-term regulation on nanotechnology 
seems technically problematic and politically improbable and hence the Commission of 
the European Communities has adopted an incremental approach making consistent use 
of existing regulation when this can be easily applied as such or suitably amended 
Through an in-depth analysis of key pieces of regulation such as REACH, 
pharmaceutical regulation and the worker safety directives, a number of limitations of 
the current legislation were identified. Although nanomaterials might be covered by the 
general scope of many of the existing legislative frameworks, it is often unclear if 
nanoparticles actually are covered when it comes to specific nanomaterials and 
applications. The main problems seem to be that metrology tools are unavailable, that 
thresholds are not tailored to the nanoscale, but based on bulk material, profound lack of 
(eco)toxicological data, and that no risk thresholds and occupational exposure limits 
cannot be established with existing methodologies. So far, the only amendments that 
have been implemented in the EU is to take carbon and graphite from the list of 
substances exempted from registration under REACH which is deemed to be 
dissatisfactory to address the current regulatory uncertainty and the potential risks of 
nanomaterials.  
It is recommended that all nanomaterials are treated as new substances under 
REACH and that nanomaterials are registered based on a threshold and units different 
than mass. Besides providing the traditional physciochemical properties producers and 
importers of nanomaterials should be obliged to provide (eco)toxicological data and 
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additional information on the specific properties of nanomaterials under the help and 
guidance of the new European Chemical Agency. Key information during production, 
extraction and refining, manufacturing, use and final disposal of the products should 
also be provided to the European Chemical Agency and disclosed to the public. Without 
such information, public authorities will have a hard time monitoring and evaluating the 
effectiveness of the incremental approach.  
Although REACH is expected to provide the backbone of the “incremental” 
approach, other pieces of legislation need to be revised as well. In regard to the 
occupational exposure of nanoparticles, it is recommend that exposure is limited as 
much as possible, while international standards for the safe handling of nanoparticles is 
developed. For waste management, it is recommended to introduce “free nanoparticles” 
in Annex II of the Directive on hazardous waste whereas it is recommended that 
estimated environmental concentrations are not used as trigger values for further action 
in regard to regulation of nanomedical products. 
Several governments have opted to implement voluntary environmental 
programs (VEPs), arguing that this is the only viable proportional option for the time 
being. It is generally known that key elements of any successful VEP are: incentives to 
participate for various stakeholders, agency guidance and technical assistance, signed 
commitments and periodical reporting, quality of information, and transparency both in 
design, reporting and evaluation. However, many of these elements have not been fully 
addressed in the VEP that are implemented currently on nanomaterials.  
It is recommended that more incentives to participate in the program are 
provided. These include providing technical assistance, training and external feedback 
from independent scientists or specialists and other stakeholders. Non-technical support 
should be given as well through the publishing of various newsletters, agency guidance 
documents on determining various nanomaterial characteristics, (eco)toxicological 
testing and monitoring and favorable publicity. Disincentives should be implemented as 
well – including the creation of a list of companies not participating in the program, but 
known to develop and manufacture nanomaterials. Companies should be obligated to 
share information and insight into the basis of risk assessment and management 
decisions with other companies within the supply chain through liability laws. Finally, 
any voluntary program on nanomaterials should be made mandatory after no more than 
three years in order to create a “threat of regulatory intervention” 
Implementation of these recommendations will only address some of the 
immediate concerns related to the application of the incremental approach and voluntary 
programs to regulate current manufacturing and use of nanomaterials. However, they 
fail to address other concerns, especially the ones related to nanomaterial yet to be 
developed, the third and fourth generation of nanotechnological development. This 
strongly indicates that a new regulatory framework will be needed (RCEP 2008). 
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Risk assessment plays a fundamental role of providing decision support for 
regulators and industry in the EU’s incremental approach. The in-depth analysis of the 
current state of knowledge performed in the thesis identified a number of limitations in 
each of the four steps that together constitute the risk assessment framework.  
Toxicity has been reported on for multiple nanoparticles, but for most 
nanoparticles these need further confirmation before one can say that a hazard has been 
identified. Multiple studies relevant for hazard identification have been carried out on 
C60, CNTs, quantum dots and other nanomaterials, however, many of these studies are 
not meant to facilitate risk assessment in the sense that they use non-standardized tests, 
have no coherent endpoint, and differ substantially with regard to species tested, 
methods of administration, dose range, way of particle preparation, duration of 
exposure, and effects observed and reported. This hampers identification of hazard 
univocally for most nanoparticles. It is evident that the information provided is ‘all over 
the map’ making it impossible to systematically analyze the studies for properties of the 
nanoparticles which are important for the observed effects.  
Dose-response estimates assumes a no effect threshold can be established and 
although some studies have reported observing a dose-response relationship there is no 
evidence of a dose threshold below which nanoparticle instillation ceased to cause 
inflammation. A dose-response assessment is furthermore hindered by the fact that it is 
unclear what the best descriptors for dose is and which properties determine or 
influence the inherent hazards of nanoparticles. The current lack of characterization of 
the nanoparticles tested in various studies makes it impossible to identify causality 
between observed hazards and specific physical and chemical properties. There is 
furthermore substantial limitation in our ability to determine individual and multiple 
particle characteristics simultaneously and in a consistent manner – both prior and 
during tests – when using different characterization techniques and/or across 
laboratories.  
Exposure assessment is hampered by difficulties in monitoring nanomaterial 
exposure in the workplace and the environment, and by the fact that the biological and 
environmental pathways of nanomaterials are still largely unexplored. The assessment 
of  worker exposure is hampered by both technical difficulties such as the lack of one 
consistent sampling method that can be used to characterize exposure in real-time and 
by lack of information and data, for example, about how many workers are potentially 
exposed, what kinds of nanomaterials workers are or might be exposed to, where and 
how they are exposed and at which concentrations, by dose or by particles number, and 
what kinds of protective measures there are used or available. As with worker exposure, 
analytical methods to detect and quantify concentrations of nanoparticles in the 
environment have yet to become available. The total load to the environment from 
current use of nanomaterials is unclear. Several studies have tried to assess current and 
future consumer and environmental exposure for individual products, nanomaterials, 
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and applications as well as product types. These studies, no doubt, hold great value in 
regard to assessing the applicability of exposure assessment and should be seen as 
“proof of principle” rather than actual assessment of the exposure. Paucity of 
knowledge and lack of access to information hampers realistic exposure assessments.  
Risk characterization being at the end of the line, the sum or maybe even the 
power all of these limitations are conveyed to calculating risk quotients for 
nanoparticles.   
It is concluded that that we do not know enough to say that nanomaterials are safe, 
but that there is evidence that some nanomaterials are hazardous depending on how they 
are applied and how humans and the environment are exposed to them. It is furthermore 
concluded that the existing regulation is not adequate to deal with nanomaterials in the 
short and the long term and that too little is being done currently to amend existing 
regulation through the incremental approach adopted by the EU and voluntary 
environmental program implemented in the UK. Although recognizing the adaptations 
are needed, risk assessment have repeatedly been proposed by expert committees, 
policy-makers, members of industry and non-governmental organization as means to 
inform decision makers about the risks of nanomaterials. However, in this thesis, risk 
assessment is found to be inadequate to timely inform policy-makers about the health 
and environmental risks of nanomaterials, if not in the short term, then most definitely, 
in the long term. Risk assessment is deemed not feasible for the purpose of dealing with 
the complex emerging risks of nanomaterials and will not be adequate to ensure a 
decision making process that enables us to make informed decisions within a reasonable 
period of time. 
It is recommended that current regulation is adapted immediately to reflect the 
challenges posed by current nanomaterials and their applications and that risk 
assessment is abandoned as the primary decision making tool and that alternative tools 
are pursued to support transparent and informed decision making processes.  
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